



Effect of Neuromuscular Electrical Stimulation After Total Knee Arthroplasty: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Linbo Peng^{1†}, Kexin Wang^{2†}, Yi Zeng¹, Yuangang Wu¹, Haibo Si¹ and Bin Shen^{1*}

¹ Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China, ² Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, China

OPEN ACCESS

Edited by:

Tzvi Dwolatzky, Technion Israel Institute of Technology, Israel

Reviewed by:

Changjiao Sun, Tsinghua University, China Daniela Costa, Universidade NOVA de Lisboa, Portugal

*Correspondence: Bin Shen shenbin_1971@163.com

[†]These authors have contributed equally to this work and share first authorship

Specialty section:

This article was submitted to Geriatric Medicine, a section of the journal Frontiers in Medicine

Received: 17 September 2021 Accepted: 08 November 2021 Published: 03 December 2021

Citation:

Peng L, Wang K, Zeng Y, Wu Y, Si H and Shen B (2021) Effect of Neuromuscular Electrical Stimulation After Total Knee Arthroplasty: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Med. 8:779019. doi: 10.3389/fmed.2021.779019 **Background:** This systematic review and meta-analysis aimed to evaluate the effect of neuromuscular electrical stimulation (NMES) on quadriceps muscle strength, pain, and function outcomes following total knee arthroplasty (TKA).

Methods: PubMed/Medline, Embase, Web of Science, CENTRAL, Scopus, PsycINFO, PEDro, CINAHL, CNKI, and Wanfang were systematically searched for randomized controlled trials (RCTs) from their inception to 18 June 2021.

Results: Nine RCTs that involving 691 patients were included in the meta-analysis. Our pooled analysis showed that NMES improved quadriceps muscle strength after TKA within 1 months [standardized mean difference (SMD): 0.81; 95% CI: 0.51-1.11], 1-2 months (SMD: 0.55; 95% CI: 0.13-0.97), 3-4 months (SMD: 0.42; 95% CI: 0.18-0.66), and 12–13 months (SMD: 0.46; 95% CI: 0.18-0.74), pain between 1 and 2 months [mean difference (MD): -0.62; 95% CI: -1.04 to -0.19], pain between 3 and 6 months (MD: -0.44; 95% CI: -0.74 to -0.14) Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) between 3 and 4 months (MD: -0.43; 95% CI: -0.82 to -0.05), timed up and go test (TUG) within 1 month (MD: -2.23; 95% CI: -3.40 to -1.07), 3 minutes walk test between 3 and 6 months (MD: 28.35; 95% CI: 14.55-42.15), and SF-36 MCS between 3 and 6 months after TKA (MD: 4.20, 95% CI: 2.41-5.98).

Conclusion: As a supplementary treatment after TKA, postoperative NMES could improve the short-term to long-term quadriceps muscle strength, mid-term pain, and mid-term function following TKA. However, many outcomes failed to achieve statistically meaningful changes and minimal clinically important difference (MCID), thus the clinical benefits remained to be confirmed.

Level of Evidence: Therapeutic level I.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42021265609.

Keywords: total knee arthroplasty, neuromuscular electrical stimulation, quadriceps muscle strength, pain, function, systematic review, meta-analysis

What is Known: Neuromuscular electrical stimulation was regarded as a potential approach to improve muscle contractility and postoperative quadriceps weakness. With relevant studies published, the advantage of NMES on quadriceps muscle strength, pain, and function outcomes following TKA remains controversial.

What is New: This systematic review and meta-analysis is the first to identify that postoperative NMES could improve the quadriceps muscle strength, pain, and function following the TKA surgery. The quality of evidence ranged from good to high. However, many outcomes failed to achieve statistically meaningful changes and MCID, thus the clinical benefits remained to be confirmed.

INTRODUCTION

Total knee arthroplasty (TKA) is one of the most common and cost-effective procedures for patients with end-stage osteoarthritis of the knee, which has been performed with increasing frequency in recent years (1, 2). Although TKA provides patients with reduced pain and a functional range of motion (ROM) of the knee joint, quadriceps strength impairment is common following the surgery (3). Besides, almost all patients suffer from postoperative pain with different levels, which affect postoperative satisfaction and outcomes (4). Studies have shown that nearly 20% of primary TKA patients were not satisfied with their outcomes following the surgery (5).

Standardized physical therapy and pharmacologic analgesia improve muscle strength and pain after TKA (6). However, the content of rehabilitation varies worldwide (7, 8). Electrical stimulation is effective in accelerating recovery from surgery (9). Neuromuscular electrical stimulation (NMES) has been utilized since the eighteenth century (10). It was regarded as a potential approach to improve muscle contractility and postoperative quadriceps weakness (11). A systematic review involving a total of 933 participants found that NMES may be an effective treatment for muscle weakness and should be regarded as a crucial part of rehabilitation programs (12). The advantages of NMES have been emphasized in many diseases such as anterior cruciate ligament injury, neck pain, stroke, and cerebral palsy (13–17).

Recently, some studies have examined the effect of NMES following TKA but remain controversial (18–23). The clinical effectiveness of NMES following TKA on quadriceps muscle

strength, pain, and function outcomes remains unclear. We conduct this meta-analysis to evaluate the effect of NMES on quadriceps muscle strength, pain, and function outcomes following TKA further.

METHODS

This study was based on the previous published RCTs. Thus, the ethical approval and consent to participate were not necessary. This systematic review and meta-analysis is performed following the Cochrane Handbook for Systematic Reviews of Interventions (24) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (25). The protocol was registered in the PROSPERO (Registration number: CRD42021265609).

Search Strategy

The PubMed/Medline, Embase, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, PsycINFO, Physiotherapy Evidence Database (PEDro), CINAHL, China National Knowledge Infrastructure (CNKI), and Wanfang (a Chinese database) were systematically searched for randomized controlled trials (RCTs) from their inception to 18 June 2021 by two independent reviewers (LBP and KXW). The search strategies were shown in **Appendix 1**.

Eligibility Criteria

The studies included in the meta-analysis were required to meet the following inclusion criteria: (1) Patients: adult patients undergoing primary TKA; (2) Intervention: postoperative NMES. NMES was utilized in the intervention group after the TKA surgery. Patients who received preoperative NMES were excluded; (3) Comparison: conventional rehabilitation or conventional physical therapy. Patients who received any form of electrical stimulation in the control group were excluded; (4) Outcomes: The primary outcome measures, such as quadriceps muscle strength [maximal volitional isometric contraction (MVIC)], physiological cost index (PCI), pain such as visual analog scale (VAS), and numerical pain rating scale (NPRS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Timed Up and Go Test (TUG), Stair-Climbing Test (SCT), 3 Minutes Walk Test (3MWT), 6 Minutes Walk Test (6MWT), range of motion (ROM), and 36-Item Short-Form Health Survey (SF-36); (5) Study design: randomized controlled trials (RCTs); language and published time restrictions were not employed.

Maximal volitional isometric contraction is a classic method to calculate muscle strength for patients with neuromuscular disorders by providing intrinsic factors such as units of kilograms and Newtons of force (26). As a measure of energy cost, PCI was calculated by dividing the heart rate increase (heart rate at the end of the 3MWT minus resting heart rate) by walking speed (m/min) (18, 21). A lower PCI score indicated a lower energy cost during walking (27). To assess the TUG score, patients were asked to rise from an armchair, walk 3 m away, then turn and walk back to sit down on the same chair (28, 29). The TUG is an excellent representation of essential mobility,

Abbreviations: NMES, neuromuscular electrical stimulation; TKA, total knee arthroplasty; PRISMA, preferred reporting items for systematic reviews and metaanalyses; ROM, range of motion; RCT, randomized controlled trial; MCS, mental component score; PCS, physical component score; SF-36, 36-item short form health survey; CENTRAL, Cochrane central register of controlled trials; CNKI, China national knowledge infrastructure; PCI, physiological cost index; VAS, visual analog scale; NPRS, numerical pain rating scale; WOMAC, western ontario and mcmaster universities osteoarthritis index; TUG, timed up and go test; SCT, stair climbing test; 3MWT, 3 minutes walk test; 6MWT, 6 minutes walk test; MD, mean difference; SMD, standardized mean difference; MVIC, maximal voluntary isometric contraction; BMI, body mass index; mMMES, motor-level NMES; sNMES, sensory-level NMES; KOS ADLS, knee outcome survey activities of daily living scale; HRQoL, health-related quality-of-life; MCID, minimal clinically important difference.

strength, balance, and agility (29). The SCT was used to assess the lower extremity strength, power, and balance (29). The 3MWT is a simple, non-incremental, and easy to conduct submaximal strength test (30). As a standard walking test, 6MWT has been widely used to determine the progress following rehabilitation

intervention (31). The SF-36 is the most widely used healthrelated quality-of-life (HRQoL) in the USA (32). The SF-36 is consists of eight individual subscales. Scores of those subscales can be combined into two higher-order summary scores: PCS and MCS (33).




FIGURE 1 | Flow chart of studies selection according to preferred reporting items for systematic reviews and meta-analyses guidelines. EMBASE, Excerpta Medica Database; CENTRAL, Cochrane Central Register of Controlled Trials; PEDro, Physiotherapy Evidence Database; CNKI, China National Knowledge Infrastructure; TKA, Total Knee Arthroplasty; NMES, Neuromuscular electrical stimulation; RCT, Randomized Controlled Trial.

TABLE 1 | Characteristics of studies included in the meta-analysis.

Author(s)/year/ country/design	Patients (I: C); female proportion (I: C)	Age (I: C)	BMI (I: C)	Intervention vs. control	Intervention frequency, duration, and time	Intervention intensity	Main outcome measures
Avramidis et al. /2003/UK/2-arm RCT	15(l):15(C); 10/15(l):12/15(C)	68.20 ± 10.59(l): 71.20 ± 7.83(C)	Not mentioned	NMES+ conventional PT vs. Conventional PT	NMES (40 Hz, 300 μ s) of the vastus medialis for 2 h on each occasion, twice daily, from the second day postoperative to the 6 weeks postoperative	Maximum tolerable intensity	3MWT, PCI, HSS at 6, 12 weeks postoperatively
Petterson et al./2009/US/2-arm RCT	100(l): 100(C); 47/100(l): 45/100(C)	65.3 ± 8.3(l): 65.2 ± 8.5(C)	29.67 ± 4.85 (l): 29.99 ± 3.90 (C)	NMES+ exercise vs. Exercise	NMES 2 or 3 times per week for 6 weeks with a minimum requirement of 12 therapy visits		SF-36 (PCS, MCS), KOS-ADLS, pain-KOS, TUG, SCT, 6MWT, active flexion ROM, active extension ROM and CAR (NMVIC, newtons/BMI) at 3, 12 months postoperatively
Valdés et al./2010/Spain/2- arm RCT	39(l): 44(C); 25/39(l): 25/44(C)	72 \pm 6(l): 70 \pm 7(C)	32.3 ± 4.7(l): 32.4 ± 6.3(C)	NMES+ standard rehabilitation vs. Standard rehabilitation	NMES (65 Hz, 300 μ s, 15–30 mA) of feedback to the quadriceps for 15 min once a day from the day after surgery	Not mentioned	BA, TUG, WOMAC pain, WOMAC stiffness, WOMAC function at 1, 3 months; LOS
Avramidis et al. /2011/Greece/2- arm RCT	35(l): 35(C); 28/35(l): 29/35(C)	70.54 ± 4.68(l): 70.66 ± 3.73(C)	27.38 ± 2.65(l): 27.14 ± 3.31(C)	NMES+ conventional physiotherapy vs. Conventional physiotherapy	NMES (40 Hz, 300 $\mu s)$ of the vastus medialis muscle twice daily for 2 h from the second postoperative day	Maximum tolerable intensity	AKSS, OKS, SF-36, 3MWT, PCI at 6, 12, and 52 weeks postoperatively
Stevens-Lapsley et al./2012/US/2-arm RCT	35(l): 31(C); 20/35(l): 16/31(C)	()	27.1 ± 4.9 (I): 31.2 ± 4.2 (C)	NMES+ standard rehabilitation vs. Standard rehabilitation	NMES (600 μs) twice daily from 2 days after surgery	Maximum tolerable intensity	Quadriceps and hamstring muscle strength, TUG, SCT, 6MWT, NPRS, active flexion ROM, active extension ROM, SF-36 (PCS, MCS), WOMAC, GR at 3.5, 6.5, 13, 26, 52 weeks postoperatively
Levine et al./2013/US/2-arm RCT	35(l): 35(C); 25/35(l): 21/35(C)	68.1(l): 65.1(C)	30.6(l): 31.9(C)	NMES+ ROM exercise vs. therapist- managed PT	NMES used from the second day postoperatively	Not mentioned	KSS pain, KSS function, WOMAC, passive flexion ROM, passive extension ROM, TUG at 6 weeks an 6 months postoperatively
Demet et al./2015/Turkey/2- arm RCT	30(l): 30(C); 28/30(l): 29/30(C)	66.2 ± 7.2(l): 64.6 ± 6.6(C)	$\begin{array}{l} 29.1 \pm 3.9 (\text{I}): 30.1 \\ \pm 4.6 (\text{C}) \end{array}$	NMES+ exercise vs. Exercise	NMES (30–100 Hz, 400 μ s, 28–90 mA) of the vastus medialis muscle for 30 min, 5 days a week from the first day postoperatively.	Maximum tolerable intensity	flexion ROM, extension ROM, TUG, WOMAC, SF-36, VAS at 1, 3 months postoperatively
Yoshida et al./2017/Japan/3- arm RCT	22 (sNMES): 22 (mNMES): 22 (Control): 18/22 (sNMES): 18/22 (mNMES): 20/22 (Control)	71.6 ± 7.0 (sNMES):75.9 ± 4.7 (mNMES):72.5 ± 6.2 (Control)	25.4 ± 2.2 (sNMES): 24.6 ± 2.9 (mNMES): 25.8 ± 3.3 (Control)	sNMES+ standard rehabilitation vs. mNMES+ standard rehabilitation vs. Standard rehabilitation	sNMES (100 Hz, 1 ms, 10–15 mA, 45 min/day) and mNMES (100 Hz, 1 ms, 15–38 mA, 45 min/day) 5 days/week for 2 weeks from the second weeks postoperatively	Sensory-level intensity (sNMES) and maximum tolerable intensity (mNMES)	MVIC, LSMM, TUG, 2MWT, VAS (0–100 mm), passive flexion ROM and passive extension ROM a 2 weeks postoperatively
Klika et al./2020/US/2-arm RCT	24(l): 22(C); 18/24(l): 17/22(C)	65 ± 5.8 (l): 65 ± 7.6 (C)	Not mentioned	NMES+ standard PT vs. Standard PT	NMES (15–85 V, 50 pps, 5 ms) for 200 min/week, 12 weeks from the day of surgery	Maximum tolerable intensity	Quadriceps strength, ROM, resting pain, TUG, SCT KOOS and VR-12 at 3, 6, and 12 weeks postoperatively

I, Intervention; C, Control; BMI, body mass index; RCT, randomized controlled trial; NMES, neuromuscular electrical stimulation; PT, physical therapy; 3MWT, 3-minute walking test; PCI, hysiological Cost Index; HSS, Hospital for Special Surgery knee score; ROM, range of motion; TUG, timed up and go test; 6MWT, 6-minute walk test; MVIC, normalized maximal volitional isometric contraction; CAR, the central activation ratio; BMI, body mass index; SCT, stair climbing test; SF-36, Short Form 36; PCS, physical component score; MCS, mental component score; KOS ADLS, Knee Outcome Survey Activities of Daily Living scale; BA, balance articular; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; LOS, length of stay; AKSS, American Knee Society clinical score; OKS, Oxford knee score; NPRS, Numeric Pain Rating Scale; GRS, global rating scale; KSS, knee Society score; VAS, visual analogue scale; sNIMES, sensory-level neuromuscular electrical stimulation; LSMM; leg skeletal muscle mass; 2MWT, 2-minute walk test; KOOS, Knee injury and Osteoarthritis Outcome Score; VR-12, veterans rand-12.

Study Selection

Firstly, all the identified studies were imported into the Endnote X9 (Thomson Reuters, CA, USA). After removing the duplicate studies, two reviewers (YGW and HBS) scanned the titles, abstracts, and full texts independently. Any disagreements were resolved by discussion with a senior reviewer (YZ). Commentaries, letters, case reports, trial protocols, reviews, and retrospective studies were excluded from our systematic review and meta-analysis.

Data Extraction

Two authors (LBP and YGW) extracted the following data independently and discussed with a senior reviewer (HBS) if disagreements existed. The extracted data including the publication data (the name of the author; publication year; country; study design), demographic characteristics [number of patients, age, sex, body mass index (BMI)], characteristics of the intervention (frequency, duration, intensity of the NMES program), rehabilitation type of the control group, outcomes data (quadriceps muscle strength, PCI, VAS, NPRS, WOMAC, TUG, SCT, 3MWT, 6MWT, ROM, and SF-36).

Study Quality Assessment

Two authors (KXW and YZ) evaluated the methodological quality of the included studies independently with the Cochrane bias risk assessment tool and discussed with a senior reviewer (BS) if any disagreements existed (34). Each study was documented with low, high, or unclear risk of bias in each domain.

Statistical Analysis

The review manager software (RevMan 5.3, Oxford, United Kingdom) was used to conduct our meta-analysis and produce forest plots. All the continuous variable outcomes were presented as the mean difference (MD) with a 95% CI

to calculate the total effect of NMES on patients following TKA. The standardized mean difference (SMD) was used to calculate the total effect if different scales were utilized among the studies (35). I^2 statistics measured heterogeneity among the studies. The random-effects model was used if substantial heterogeneity exists (P < 0.05 or $I^2 > 50\%$). If not, the fixed-effects model was adopted. A P < 0.05 demonstrated a statistically significant difference.


RESULTS

Study Selection

A total of 761 studies were identified from the initial search. After removing 344 records for duplicates, 353 studies were excluded by screening the title and abstract. After excluding three studies for not being retrieved, the remaining 61 studies were screened the full-text for eligibility. Fifty-two reports were excluded by screening the full-text: not NMES (n = 19); not postoperative intervention (n = 3); not conventional rehabilitation in the control group (n = 3); not RCT (n = 8); retrospective study (n = 2); protocol (n = 8); review (n = 4); not TKA (n = 2); and outcomes not related (n = 3). The remaining nine RCTs involving 691 patients met the eligibility criteria and were included in the meta-analysis (18, 19, 21, 22, 36–40). The PRISMA flow diagram was shown in **Figure 1**.

Study Characteristics


Among all the included studies, eight were 2-arm RCTs (18, 19, 21, 22, 36–38, 40) and one was 3-arm RCTs (39). The average sample size was 77 patients (ranging from 30 to 200). The follow-up periods of each article ranged from 4 to 52 weeks. Three hundred and fifty-seven patients received NMES therapy following TKA surgery, while 334 received conventional rehabilitation therapy. The included trials were performed in different countries: one in the UK (18), four in the USA (19, 22,



	tion (selection bias)	election bias)	Blinding of participants and personnel (performance bias)	sment (detection bias)	attrition bias)	ng bias)		
	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants ar	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias	
Avramidis 2003	•	?	•	?	•	•	•	
Avramidis 2011	•	?		•	•	•	•	
Demircioglu 2015	+	?		?	•	+	•	
Klika 2020	•	?		•		•	•	
Levine 2013	+	?		?	?	+	+	
Petterson 2009	+	?		+	?	+	+	
Stevens-Lapsley 2012	•	?		?	?	+	•	
Valdés 2010	•	?		•	?	+	?	
Yoshida 2017	•	?		•	•	+	•	
FIGURE 3 Risk of bias summary for each included studies.								

		eriment			control			Std. Mean Difference		Std. Mean Difference
tudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	Year	IV. Random, 95% Cl
2.1.1 < 1 month										
tevens-Lapsley 2012	0.93	0.41	31	0.66	0.24	28	7.5%	0.78 [0.25, 1.31]		
oshida a 2017	0.26	0.05	22	0.19	0.07	22	5.2%	1.13 [0.49, 1.77]		
oshida b 2017	0.24			0.19	0.07	22	5.7%	0.70 [0.09, 1.31]		
lika 2020	4.77	19.19		-8.92	22.7	18	5.2%	0.64 [0.00, 1.28]	2020	
ubtotal (95% Cl)			97			90	23.7%	0.81 [0.51, 1.11]		
leterogeneity: Tau ² = 0	.00; Chi ²	= 1.35,	df = 3	(P = 0.7	2); ² =	0%				
est for overall effect: Z	= 5.28 (P < 0.00	0001)							
2.1.2 1-2 months										
itevens-Lapsley 2012	1.2	0.47	31	1.04	0.35	28	8.0%	0.38 [-0.14, 0.89]	2012	
lika 2020	9.35	18.75	22	-5.48	16.53	18	5.0%	0.82 [0.17, 1.47]		
ubtotal (95% CI)			53			46	13.0%	0.55 [0.13, 0.97]		
leterogeneity: Tau ² = 0	.01: Chi ²	= 1.07.	df = 1	(P = 0.3)	0): ² =	7%				
est for overall effect: Z					-,, -					
2.1.3 3-4 months										
etterson 2009	19.05	4.02	76	17.35	4.02	92	22.6%	0.42 [0.11, 0.73]	2009	
tevens-Lapsley 2012	1.42		30	1.2		29	8.0%	0.46 [-0.06, 0.98]		
(lika 2020		14.29	22		24.41	18	5.4%	0.35 [-0.28, 0.98]		
ubtotal (95% CI)			128			139	36.0%	0.42 [0.18, 0.66]		
leterogeneity: Tau ² = 0	00: Chi2	= 0.07	df = 2	P = 0.9	7): ² =	0%				
est for overall effect: Z										
2.1.4 12-13 months										
etterson 2009	22.64	4.02	68	20.6	4.02	81	19.9%	0.50 [0.18, 0.83]	2009	
tevens-Lapsley 2012	1.66	0.52	30	1.5	0.43	25	7.5%	0.33 [-0.21, 0.86]		
Subtotal (95% CI)		0.01	98	1.0	0.40	106	27.3%	0.46 [0.18, 0.74]		
leterogeneity: Tau ² = 0	00. Chia	= 0.31		P = 0.5	8)· ² =			and found on the		-
est for overall effect: Z				(1 - 0.0	0), 1	070				
otal (95% Cl)			376			381	100.0%	0.54 [0.39, 0.68]		•
leterogeneity: Tau ² = 0	00: Chi ²	= 7.17		$(\mathbf{P} = 0)$	71): ² =			,,		
est for overall effect: Z				U .	,,	270				-1 -0.5 0 0.5 1
est for subaroup difference. 2			,							Favours [control] Favours [experimental]

FIGURE 4 | Forest plots of meta-analysis of the effect of neuromuscular electrical stimulation (NMES) vs. conventional rehabilitation on quadriceps muscle strength.



37, 40), one in Spain (36), one in Greece (21), one in Turkey (38), and one in Japan (39). All the characteristics of included studies were presented in **Table 1**.

Interventions

All the involved patients received similar conventional rehabilitation/physical therapy/exercise. Besides, patients in the NMES groups received similar NMES therapy in all the included nine RCTs. The frequency of NMES ranged from 30 to 100 Hz, and the duration ranged from 300 µs to 1 ms in six studies (18, 21, 22, 36, 38, 39). Klika et al. set the frequency as 50 pps and the pulse width as 5 ms (40). Two studies did not document the frequency and duration data of the NMES protocol (19, 37). Three RCTs reported that the NMES therapy was used twice daily (18, 21, 22). Petterson et al. (19) conducted NMES therapy 2 or 3 times per week in the experimental group, while the other two pieces of literature (38, 39) utilized it 5 days per week. Valdés et al. adopted the NMES for 15 min once a day began from the day after surgery (36). NMES was conducted in the research of Klika et al. for 200 min per week (40). Seven studies utilized the NMES with maximum tolerable intensity (18, 19, 21, 22, 38–40). The other two RCTs did not report the intensity data of NMES (36, 37). The intervention characteristics were shown in **Table 1**.

Study Quality Assessment

The risk of bias of all the included studies varied substantially. Allocation concealment bias was unclear in all nine studies (18, 19, 21, 22, 36–40). All the studies failed to achieve performance bias (18, 19, 21, 22, 36–40). Five RCTs implied the blinded assessors in their studies (19, 21, 36, 39, 40). The risk of bias graph for each study and the risk of bias summary was shown in **Figures 2, 3**.

Outcomes

Quadriceps Muscle Strength

Four studies reported the quadriceps muscle strength (19, 22, 39, 40). Since the included studies adopt different intrinsic factors to normalize MVIC values, the SMD was used to calculate the total effect of quadriceps muscle strength. Our pooled analysis involving four studies indicated that NMES improved MVIC after TKA within 1 month (SMD: 0.81; 95% CI: 0.51–1.11, P <

	•	erimen			ontrol			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% Cl
9.1.1 < 1 month										
Stevens-Lapsley 2012	1.8	1.7	30	2.1	1.8	26	4.4%	-0.30 [-1.22, 0.62]		
Yoshida b 2017	2.9	2.6	22	3.1	2.3	22	2.0%	-0.20 [-1.65, 1.25]		
Yoshida a 2017	2	1.2	22	3.1	2.3	22	3.4%	-1.10 [-2.18, -0.02]		
Klika 2020	3	2.96	24	3	2.22	22	1.9%	0.00 [-1.50, 1.50]	2020	
Subtotal (95% CI)			98			92	11.6%	-0.47 [-1.05, 0.11]		
Heterogeneity: Tau ² = 0.0				(P = 0.5	9); l² =	0%				
Test for overall effect: Z =	: 1.58 (P	= 0.11)							
9.1.2 1-2 months										
Valdés 2010	2.7	1.7	39	3.05	1.5	44	6.6%	-0.35 [-1.04, 0.34]	2010	
Stevens-Lapsley 2012	0.6	0.9	29	1.2	1.3	24	7.8%	-0.60 [-1.21, 0.01]		
Demircioglu 2015	4.3	0.7	30	5.3		30	13.9%	-1.00 [-1.33, -0.67]		_ _
Klika 2020		1.48	24		1.84	22	4.0%	0.00 [-0.97, 0.97]		
Subtotal (95% CI)			122			120	32.4%	-0.62 [-1.04, -0.19]		◆
Heterogeneity: Tau ² = 0.0	09; Chi ^₂ :	= 5.99	df = 3	(P = 0.1	1); ² =	50%				
Test for overall effect: Z =	2.85 (P	= 0.00	(4)							
9.1.3 3-6 months										
Petterson 2009	2.22		76	2.16	1.83	92	9.8%	0.06 [-0.44, 0.56]	2009	
Valdés 2010	1.55	1.1	39	2	1.5	44	8.6%	-0.45 [-1.01, 0.11]	2010	
Stevens-Lapsley 2012	0.6	1.2	30	1.5	2.1	26	4.4%	-0.90 [-1.81, 0.01]		
Demircioglu 2015	2.9	0.5	30	3.5		30	15.3%	-0.60 [-0.88, -0.32]		
Klika 2020	0	1.48	24	0.5	2.22	22	3.3%	-0.50 [-1.60, 0.60]	2020	
Subtotal (95% CI)			199			214	41.4%	-0.44 [-0.74, -0.14]		-
Heterogeneity: Tau ² = 0.0				(P = 0.2)	0); l² =	33%				
Test for overall effect: Z =	: 2.84 (P	= 0.00	15)							
9.1.4 > 6 months										
Petterson 2009	1.64	1.5	68	1.78	1.83	81	9.1%	-0.14 [-0.67, 0.39]	2009	
Stevens-Lapsley 2012	0.6	1.4	29	0.4		23	5.4%	0.20 [-0.60, 1.00]		_
Subtotal (95% CI)	0.0		97	0.1	1.0	104	14.6%	-0.03 [-0.48, 0.41]	2012	
Heterogeneity: Tau ² = 0.0	00: Chi ² :	= 0.48	df = 1	(P = 0.4)	9): l² =					
Test for overall effect: Z =		101111			-,,	• • •				
			, 							
Total (95% CI)			516			530	100.0%	-0.45 [-0.66, -0.23]		◆
Heterogeneity: Tau ² = 0.0	06; Chi ² :	= 22.7	0, df = 1	4 (P = 0	0.07);1	² = 38%	6		-	
Test for overall effect: Z =	4.03 (P	< 0.00	01)							-2 -1 U 1 2 Favours [experimental] Favours [control]
Test for subaroup differe	nces: Cl	hi² = 3.	74. df=	= 3 (P =	0.29).	l ² = 19.	8%			ravous (experimental) ravous (control)

FIGURE 6 | Forest plots of meta-analysis of the effect of NMES vs. conventional rehabilitation on pa

		eriment			Control			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
8.1.1 < 1 month										
Stevens-Lapsley 2012	26.6	12	28	31.4	14.1	21	11.1%	-0.37 [-0.94, 0.21]	2012	
Subtotal (95% CI)			28			21	11.1%	-0.37 [-0.94, 0.21]		
leterogeneity: Not appli										
fest for overall effect: Z =	1.25 (P	= 0.21)								
8.1.2 1-2 months										
Stevens-Lapsley 2012	18.1	8.9	29	23.7	14.2	24	11.3%	-0.48 [-1.02, 0.07]	2012	
evine 2013	75.86	13.41	30	70.19	17.08	33	11.5%	0.36 [-0.14, 0.86]	2013	
Demircioglu 2015	53.4	6.4	30	77.3	9.5	30	10.2%	-2.91 [-3.65, -2.17]	2015	
Subtotal (95% CI)			89			87	33.0%	-0.99 [-2.71, 0.74]		
Heterogeneity: Tau ² = 2.2	23; Chi ² =	= 52.08,	df = 2	(P < 0.0	0001);	²= 969	6			
fest for overall effect: Z =	1.12 (P	= 0.26)								
8.1.3 3-4 months										
Stevens-Lapsley 2012	11.2	8.7	26	18	17.6	21	11.1%	-0.50 [-1.08, 0.09]	2012	
Demircioalu 2015	42.3	11.3	30	47.2	13.8	30	11.4%	-0.38 [-0.89, 0.13]	2015	
Subtotal (95% CI)			56			51	22.5%	-0.43 [-0.82, -0.05]		•
Heterogeneity: Tau ² = 0.0	J0; Chi ² =	= 0.08, (∜f=1 (f	P = 0.77); $l^2 = 0^9$	%				
est for overall effect: Z =	2.21 (P	= 0.03)								
8.1.4 6-7 months										
Stevens-Lapsley 2012	7.5	6.6	28	13.6	11.6	21	11.1%	-0.66 [-1.24, -0.08]	2012	
evine 2013	86.61	14.68	26	80.8	16.95	24	11.2%	0.36 [-0.20, 0.92]		
Subtotal (95% CI)			54			45	22.3%	-0.15 [-1.15, 0.86]		
Heterogeneity: Tau ² = 0.4	4; Chi ² =	= 6.17, 0	df = 1 (f	P = 0.01); l² = 84	1%				
fest for overall effect: Z =	0.29 (P	= 0.77)								
9.1.5 13 months										
Stevens-Lapsley 2012	5.7	5.9	26	10	12.2	21	11.1%	-0.46 [-1.04, 0.13]	2012	
Subtotal (95% CI)	5.7	3.5	26	10	12.2	21	11.1%	-0.46 [-1.04, 0.13]	2012	•
leterogeneity: Not appli	ahle		20			21		0.10[-1.01, 0.10]		•
		= 0.12)								
fest for overall effect: Z =			253			225	100.0%	0.531.4.06 0.041		
				0 - 0 0	00042-			-0.53 [-1.06, -0.01]		
otal (95% CI)	C. O	64 44			111111111	-= 879	0			
fotal (95% CI) Heterogeneity: Tau² = 0.6			df = 8	(F < 0.0	00017,1					-4 -2 0 2 4
otal (95% CI)	1.99 (P	= 0.05)		•						-4 -2 0 2 4 Favours [experimental] Favours [control]

FIGURE 7 | Forest plots of meta-analysis of the effect of NMES vs. conventional rehabilitation on the Western Ontario and McMaster Universities Osteoarthritis Index.

0.01, $I^2 = 0\%$), 1–2 months (SMD: 0.55; 95% CI: 0.13–0.97, P = 0.01, $I^2 = 7\%$), 3–4 months (SMD: 0.42; 95% CI: 0.18–0.66, P < 0.01, $I^2 = 0\%$), and 12–13 months (SMD: 0.46; 95% CI: 0.18–0.74, P < 0.01, $I^2 = 0\%$). There was no significant heterogeneity ($I^2 = 0, 7, 0, and 0\%$, respectively). The forest plot of quadriceps muscle strength was shown in **Figure 4**.

PCI

Two studies evaluated the PCI (18, 21). NMES could not improve PCI between 3 and 6 months or 12 and 13 months after TKA compared with the control group (MD: 0.02; 95% CI: -0.02-0.06, P = 0.34; MD: 0.01; 95% CI: -0.03-0.06, P = 0.54; respectively). We found no significant heterogeneity ($I^2 = 0\%$; $I^2 = 8\%$; respectively). The forest plot of PCI was shown in **Figure 5**.

Pain

Five studies assessed the pain scores during the rehabilitation procedure (19, 22, 38–40). Our pooled analysis comprising 168 patients demonstrated that NMES could not improve pain after TKA compared with the control group (MD: -0.47; 95% CI: -1.05-0.11, P = 0.11). No significant heterogeneity was found ($I^2 = 0$ %). The NMES significantly improved pain between

1 and 2 months after TKA (MD: -0.62; 95% CI: -1.04 to -0.19, P = 0.004). No significant heterogeneity was detected ($I^2 = 50\%$). NMES improved pain between 3 and 6 months after TKA without significant heterogeneity (MD: -0.44; 95% CI: -0.74 to -0.14, P = 0.005, $I^2 = 33\%$). Besides, no significant difference was found among the groups for more than 6 months (MD: -0.03; 95% CI: -0.48-0.41, P = 0.88, $I^2 = 0\%$). The forest plot of the pain score was shown in **Figure 6**.

WOMAC

A total of three studies reported the effect of NMES on WOMAC following TKA (22, 37, 38). Our pooled analysis involving three studies (22, 37, 38) revealed that NMES could not improve WOMAC between 1 and 2 months (SMD: -0.99; 95% CI: -2.71-0.74, P = 0.26). There was significant heterogeneity between the articles ($I^2 = 96\%$). Nevertheless, NMES significantly improved WOMAC between 3 and 4 months after TKA (MD: -0.43; 95% CI: -0.82 to -0.05, P = 0.03). No significant heterogeneity was detected among the studies ($I^2 = 0\%$). We failed to find a significant difference in WOMAC between 6 and 7 months (MD: -0.15; 95% CI: -1.15-0.86, P = 0.77, $I^2 = 84\%$). The forest plot of WOMAC was shown in **Figure 7**.

TUG

Six articles documented the effect of NMES on TUG following TKA (19, 22, 36–39). NMES improve TUG within 1 month

after TKA compared with the control group (MD: -2.23; 95% CI: -3.40 to -1.07, P = 0.0002). There was no significant heterogeneity among the articles ($I^2 = 3\%$). However, NMES

		rimen			ontrol			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
10.1.1 < 1 month										
Stevens-Lapsley 2012	10.4	3.8	31	13.9	4.5	28	5.5%	-3.50 [-5.64, -1.36]	2012	
Yoshida b 2017	10	13.1	22	10.6	2.7	22	1.2%	-0.60 [-6.19, 4.99]		
íoshida a 2017	8.8	1.8	22	10.6	2.7	22	8.3%	-1.80 [-3.16, -0.44]	2017	
Subtotal (95% CI)			75			72	15.0%	-2.23 [-3.40, -1.07]		-
Heterogeneity: Tau ² = 0.0				(P = 0.38	5); l² =	3%				
Test for overall effect: Z =	3.75 (P	= 0.00	02)							
10.1.2 1-2 months										
/aldés 2010	17	7.2	39	15.2	6.5	44	3.6%	1.80 [-1.17, 4.77]	2010	
Stevens-Lapsley 2012	8	2.1	31	11.3	6.8	26	4.0%	-3.30 [-6.02, -0.58]		
Levine 2013	13.53	4.14	30	12.21		33	6.7%	1.32 [-0.45, 3.09]		
Demircioglu 2015		1.9	30	13.7	1.5	30	10.6%	-0.90 [-1.77, -0.03]		
Subtotal (95% CI)			130			133	24.8%	-0.28 [-2.11, 1.56]		
Heterogeneity: Tau ² = 2.4	0; Chi ² =	= 11.27	7. df = 3	P = 0.0	01); I ² :	= 73%				
Test for overall effect: Z =										
10.1.3 3 months										
Petterson 2009	8.29	3.92	76	8.02	3.64	92	9.3%	0.27 [-0.88, 1.42]	2009	
/aldés 2010	9.7	2.8	39	10.5	6.4	44	5.6%	-0.80 [-2.89, 1.29]	2010	
Stevens-Lapsley 2012	7.5	2.2	30	9.5	2.8	30	8.7%	-2.00 [-3.27, -0.73]	2012	
Demircioglu 2015	12.3	2.1	30	12.9	1.9	30	9.9%	-0.60 [-1.61, 0.41]	2015	
Subtotal (95% CI)			175			196	33.5%	-0.75 [-1.73, 0.23]		
Heterogeneity: Tau ² = 0.5				(P = 0.08	3); l² =	56%				
Test for overall effect: Z =	1.50 (P	= 0.13)							
10.1.4 6-13 months										
Petterson 2009	8.07	3.92	68	7.68	3.64	81	8.9%	0.39 [-0.83, 1.61]	2009	
Stevens-Lapsley 2012	7.1	2	31	8.6	2.1	26	9.6%	-1.50 [-2.57, -0.43]	2012	
Levine 2013	10.64	2.88	25	10.25	2.11	24	8.1%	0.39 [-1.02, 1.80]	2013	
Subtotal (95% CI)			124			131	26.7%	-0.29 [-1.60, 1.02]		-
Heterogeneity: Tau ² = 0.9	15; Chi ² =	= 6.86,	df = 2	(P = 0.03	3); l² =	71%				
Test for overall effect: Z =	0.43 (P	= 0.67)							
fotal (95% CI)			504				100.0%	-0.76 [-1.41, -0.10]		
Heterogeneity: Tau ² = 0.8				3 (P = 0	.0009); l² = 6	3%			-4 -2 0 2 4
Test for overall effect: Z = Test for subaroup differe										Favours [experimental] Favours [control]

FIGURE 8 | Forest plots of meta-analysis of the effect of NMES vs. conventional rehabilitation on the timed up and go test.

	Expe	rimen	tal	C	Control			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% Cl
5.1.1 3-4 months										
Petterson 2009	14.28	6.82	76	12.78	12.56	92	28.0%	1.50 [-1.49, 4.49]	2009	
Stevens-Lapsley 2012	13.6	7.1	30	16.3	7.5	30	23.4%	-2.70 [-6.40, 1.00]	2012	
Subtotal (95% CI)			106			122	51.4%	-0.45 [-4.56, 3.65]		
Heterogeneity: Tau ² = 5.	88; Chi² ⊧	= 3.00,	df = 1	(P = 0.0	8); l² = 6	7%				
Test for overall effect: Z =	= 0.22 (P	= 0.83)							
5.1.2 12-13 months										
Petterson 2009	13.62	6 82	68	11 75	12.56	81	26.7%	1.87 [-1.31, 5.05]	2009	
Stevens-Lapsley 2012		4.3	29		9.3	25	21.9%	-3.30 [-7.27, 0.67]		
Subtotal (95% CI)	11.0	4.0	97	14.0	0.0	106	48.6%	-0.57 [-5.63, 4.49]	2012	-
Heterogeneity: Tau ² = 10	00° Chi	² = 3.97		(P = 0	05): I ² =					
Test for overall effect: Z =										
			202			220	100.0%	0 44 [2 05 2 49]		
Total (95% CI)	00.01.17	0.07	203	~ ~ ~ ~		228	100.0%	-0.44 [-3.05, 2.18]		
Heterogeneity: Tau ² = 4.				(P = 0.0	<i>I</i>); h= 5	1 %				-żo -io ó io żo
Test for overall effect: Z =			·							Favours [experimental] Favours [control]
Test for subaroup differe	ences: Cl	nı*=0.	UU. df=	:1 (P =	0.97). I*	= 0%				

FIGURE 9 | Forest plots of meta-analysis of the effect of NMES vs. conventional rehabilitation on stair-climbing test.

could not improve postoperative TUG between 1 and 2 months, 3 months, or 6 and 13 months (MD = -0.28, 95% CI: -2.11-1.56, $P = 0.77, I^2 = 73\%$; MD = -0.75, 95% CI: -1.73-0.23, P = 0.13, $I^2 = 56\%$; MD = -0.29, 95% CI: $-1.60-1.02, P = 0.67, I^2 = 71\%$; respectively). The forest plot of TUG was shown in **Figure 8**.

SCT

Two RCTs assessed the effect of NMES on SCT following TKA (19, 22). NMES could not improve SCT between 3 and 4 months or 12 and 13 months after TKA (MD: -0.45, 95% CI: -4.56-3.65, P = 0.83, $I^2 = 67\%$; MD: -0.57, 95% CI: -5.63-4.49, P = 0.82, $I^2 = 75\%$; respectively). The forest plot of SCT was shown in **Figure 9**.

3MWT

Two studies evaluated the effect of NMES on 3MWT following TKA (18, 21). NMES improved 3MWT between 3 and 6 months after TKA compared with the control group (MD: 28.35; 95% CI: 14.55–42.15, P < 0.0001). There was no significant heterogeneity among the studies ($I^2 = 0$ %). However, no significant difference was detected on 3MWT between 12 and 13 months after TKA (MD: 19.06; 95% CI: -4.84–42.96, P = 0.12, $I^2 = 65$ %). The forest plot of SCT was shown in **Figure 10**.

6MWT

Two studies evaluated the effect of NMES on 6MWT following TKA (19, 22). Our pooled analysis involving those two




FIGURE 10 Forest plots of meta-analysis of the effect of NMES vs. conventional rehabilitation on 3 minutes walk test.




FIGURE 11 | Forest plots of meta-analysis of the effect of NMES vs. conventional rehabilitation on 6-minute walk test.

	Exp	eriment	al	C	ontrol			Mean Difference		Mean Difference
tudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV. Random, 95% Cl
1.1.1 < 1 month										
evens-Lapsley 2012	96.4	12.3	31	95.2	11.9	28	2.9%	1.20 [-4.98, 7.38]	2012	
oshida a 2017	121	6	22	120	5	22	10.6%	1.00 [-2.26, 4.26]		
oshida b 2017	122	4	22	120	5	22	15.7%	2.00 [-0.68, 4.68]	2017	
ubtotal (95% Cl)			75			72	29.2%	1.56 [-0.40, 3.52]		
eterogeneity: Tau ² = 0				(P = 0.8	9); l² =	0%				
est for overall effect: Z	= 1.56 (I	P = 0.12	2)							
1.1.2 1-2 months										
aldés 2010	96.8	13.4	39	99.7	13.2	44	3.4%	-2.90 [-8.64, 2.84]	2010	
tevens-Lapsley 2012	107.3	10.6		103.8	12.1	26	3.2%	3.50 [-2.46, 9.46]		
evine 2013	104.4			107.6		33	4.0%	-3.20 [-8.52, 2.12]		
emircioglu 2015	109.5	8.4		105.6	7.1	30	7.3%	3.90 [-0.04, 7.84]	2015	
ubtotal (95% CI)			130			133	17.8%	0.52 [-3.40, 4.45]		
eterogeneity: Tau ² = 9				(P = 0.0	7); l² =	57%				
est for overall effect: Z	= 0.26 (I	P = 0.79))							
1.1.3 3-4 months										
etterson 2009	115.2	9.2	76	114.7	9.5	92	14.0%	0.50 [-2.34, 3.34]	2009	
aldés 2010	108.2	10.8	39	108.5	10.3	44	5.4%	-0.30 [-4.86, 4.26]	2010	
tevens-Lapsley 2012	113.9	8.9	30	111	10	30	4.9%	2.90 [-1.89, 7.69]		
emircioglu 2015	113.2	7.7	30	110.5	7.9	30	7.2%	2.70 [-1.25, 6.65]	2015	
ubtotal (95% CI)			175			196	31.5%	1.24 [-0.65, 3.13]		
eterogeneity: Tau ² = 0				(P = 0.6	i4); l² =	0%				
est for overall effect: Z	= 1.29 (I	P = 0.20))							
.1.4 6-13 months										
etterson 2009	120.9	9.2	68	119	9.5	81	12.4%	1.90 [-1.11, 4.91]		
tevens-Lapsley 2012	119.4	6.3	30	117	9.1	25	6.3%	2.40 [-1.82, 6.62]		
evine 2013	114.5	13.01		112.2	10.56	24	2.6%	2.30 [-4.25, 8.85]	2013	
ubtotal (95% CI)			124			130	21.4%	2.10 [-0.20, 4.39]		
eterogeneity: Tau ² = 0				(P = 0.9	18); l² =	0%				
est for overall effect: Z	= 1.79 (l	P = 0.07)							
otal (95% CI)			504				100.0%	1.46 [0.40, 2.52]		
eterogeneity: Tau ² = 0				3 (P = 0.	.74); l² =	= 0%			_	-10 -5 0 5 10
est for overall effect: Z	•									Favours [control] Favours [experimental]
est for subaroup differe	nces: C	$hi^2 = 0.5$	7. df =	3(P = 0)	1 90) I2	= 0%				

FIGURE 12 | Forest plots of meta-analysis of the effect of NMES vs. conventional rehabilitation on knee flexion.

studies (19, 22) indicated that NMES could not improve 6MWT between 3 and 4 months or 12 and 13 months after TKA (MD: 26.08, 95% CI: -39.96-92.11, P = 0.44, $I^2 = 83\%$; MD: 15.78, 95% CI: -38.56-70.12, P = 0.57, $I^2 = 74\%$; respectively). The forest plot of 6MWT was shown in **Figure 11**.

ROM

Six studies evaluated the effect of NMES on knee flexion following TKA (19, 22, 36–39). NMES could not improve knee flexion within 1 month, 1 and 2 months, 3 and 4 months, or 6 and 13 months (MD: 1.56, 95% CI: -0.40-3.52, P = 0.12, $I^2 = 0\%$; MD = 0.52, 95% CI: -3.40-4.45, P = 0.79, $I^2 = 57\%$; MD: 1.24, 95% CI: -0.65-3.13, P = 0.20, $I^2 = 0\%$; MD: 2.10 95% CI: -0.20-4.39, P = 0.07; respectively). The forest plot of knee flexion was shown in **Figure 12**. Besides, the same six studies evaluated the effect of NMES could not improve knee extension within 1 month, 1–2 months, 3–4 months, or 6–13 months (MD: -0.64, 95% CI: -3.86-2.59, P = 0.70, $I^2 = 81\%$; MD = -0.72, 95% CI: -1.52-0.08, P =

0.08, $I^2 = 0\%$; MD: -0.21, 95% CI: -0.76-0.33, P = 0.44, $I^2 = 0\%$; MD: -0.01, 95% CI: -1.02-1.00, P = 0.98, $I^2 = 0\%$; respectively). The forest plot of knee extension was shown in **Figure 13**.

SF-36

Four studies assessed the effect of NMES on SF-36 PCS following TKA (19, 21, 22, 38). NMES could not improve SF-36 PCS after TKA within 3 months, 3–6 months, or more than 6 months (MD: 4.90, 95% CI: -0.53-10.34, P = 0.08, $I^2 = 78\%$; MD: 3.39, 95% CI: -1.91-8.68, P = 0.21, $I^2 = 87\%$; MD = 2.68, 95% CI: -2.23-7.58, P = 0.28, $I^2 = 90\%$). The forest plot of SF-36 PCS was shown in **Figure 14**. The same four studies also assessed the effect of NMES on SF-36 MCS following TKA (19, 21, 22, 38). NMES could not improve SF-36 MCS within 3 months, or more than 6 months (MD: 4.79, 95% CI: -1.25-10.82, P = 0.12, $I^2 = 81\%$; MD: 1.12, 95% CI: -0.68-2.93, P = 0.22, $I^2 = 0\%$, respectively). However, NMES improved SF-36 MCS between 3 and 6 months after TKA (MD: 4.20, 95% CI: 2.41-5.98, P < 0.01). No significant difference was

12.1 < 1 month izevens-Lapsley 2012 2.6 3.6 31 6.4 5.2 28 4.0% -3.80 [-6.11, -1.49] 2012 oshida 2 2017 5 5 2.2 4 4 22 3.0% 1.00 [-1.86, 3.88] 2017 oshida 2 2017 5 4 2.2 3.0% 1.00 [-1.36, 3.36] 2017 oshida 2 2017 5 4 2.2 3.0% 1.00 [-1.36, 3.36] 2017 oshida 2 2017 5 4 2.2 4 4 22 3.0% 1.00 [-1.36, 3.36] 2017 oshida 2 2017 5 4 2.2 4 4 2.2 3.0% 1.00 [-1.36, 3.36] 2017 oshida 2 2017 74 4.2 2.8 0.64 [-3.86, 2.59] 2012 1.2 1.3 2.9 4.3 2.6 4.4% -1.70 [-4.56, 1.16] 2010 oshida 2 2010 1.1 2.2 30 1.5.3% 0.60 [-1.50, 0.32] 2015 0.02 [-1.90, 1.49] 2019 0.05 1.5 0.20 [-0.19, 1.49] 1.20 [-1.52, 0.08] 1.23 2.40 1.30		•	riment			ontrol			Mean Difference		Mean Difference
tevens-Lapsley 2012 2.6 3.8 31 6.4 5.2 28 4.0% -3.80 [6.11, -1.49] 2012 cshida 2017 5 5 22 4 4 222 3.0% 1.00 [-1.68, 3.68] 2017 cshida 2017 5 4 22 4 4 22 3.3% 1.00 [-1.68, 3.68] 2017 tubtotal (95% C) 75 72 10.8% -0.64 [-3.86, 2.59] est for overall effect $Z = 0.39$ (P = 0.00); P = 81% est for overall effect $Z = 1.0.39$ (P = 0.00); P = 81% est for overall effect $Z = 1.0.39$ (P = 0.00); P = 81% est for overall effect $Z = 1.0.39$ (P = 0.00); P = 81% est for overall effect $Z = 1.000$ (Ch ² = 0.32); I ² = 0% est for overall effect $Z = 1.77$ (P = 0.08) 1.2.3 3.4 months etterson 2009 2 4.02 76 1.8 4.5 92 10.3% 0.20 [-1.09, 1.49] 2009 at des 2010 7.3 3.7 39 7.7 3.7 44 7.5% -0.40 [-1.99, 1.49] 2010 tevens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% -0.30 [-2.49, 0.89] 2012 etterson 2009 2 4.02 76 1.8 4.5 92 10.3% 0.20 [-1.09, 1.49] 2010 tevens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% -0.30 [-2.49, 0.89] 2012 etterson 2009 2 4.02 76 1.8 4.5 92 10.3% 0.20 [-1.09, 1.49] 2010 tevens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% -0.30 [-2.49, 0.89] 2012 etterson 2009 1 3.3 4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 etterson 2009 0 3.4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 etterson 2009 1 3.4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 etterson 2009 0 3.4.02 68 0.4 4.5 81 9.4% -0.03 [-1.076, 0.33] 12.4 6.13 months etterson 2009 0 1.3 4.02 68 0.4 4.5 81 9.4% -0.06 [-1.23, 2.43] 2012 evine 2013 2.58 2.86 26 3.54 6.05 24 3.1% -0.96 [-3.62, 1.70] 2013 ubtotal (95% C) 124 130 18.5% -0.06 [-3.62, 1.70] 2013 ubtotal (95% C) 124 132 (-0.03, df = 3 (P = 0.63); P = 0% est for overall effect $Z = 1.50$ (Ch ² = 0.13) (F = 0.22); P = 21% est for overall effect $Z = 1.50$ (Ch ² = 0.13) (F = 0.22); P = 21% est for overall effect $Z = 1.50$ (Ch ² = 0.12)	tudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
To shid a 2017 5 4 22 4 4 22 3.0% 1.00 [$+1.68, 3.86$] 2017 To shid a 2017 5 4 22 4 4 22 3.0% 1.00 [$+1.68, 3.86$] 2017 To shid a 2017 5 4 22 4 4 22 3.0% 1.00 [$+1.36, 3.36$] 2017 To shid a 2017 5 4 22 4 4 22 3.0% 1.00 [$+1.36, 3.36$] 2017 To shid a 2017 7 7 10.0% -0.64 [$-3.86, 2.59$] Heterogeneity: Tau" = 6.58; Chi" = 10.47, df = 2 ($P = 0.005$); P = 81% Test for overall effect: Z = 0.39 ($P = 0.70$) H1.2.2 1-2 months Addés 2010 11.4 6.9 39 13.1 6.3 44 2.7% -1.70 [$+4.56, 1.16$] 2010 Stevens-Lapsley 2012 1.2 4 31 2.9 4.3 26 4.4% -1.70 [$+3.87, 0.47$] 2012 Levine 2013 4.8 4.38 30 4.15 6.27 33 3.1% 0.65 [$+2.00, 3.01$] 2013 Deminicinglu 2015 0.5 1.5 30 1.1 2.2 30 15.5% -0.72 [$-1.52, 0.08$] Heterogeneity: Tau" = 0.00; Chi" = 2.32, df = 3 ($P = 0.51$); P = 0% Test for overall effect: Z = 1.77 ($P = 0.08$) H1.2.3 3-4 months Petterson 2009 2 4.02 76 1.8 4.5 92 10.3% 0.20 [$+1.09, 1.49$] 2009 Addés 2010 7.3 3.7 39 7.7 3.7 44 7.5% -0.40 [$+1.99, 1.19$] 2010 Subtotal (95% Ch) 175 196 45.2% -0.22 [$-0.08, 1.249, 0.38$] 2011 Demincinglu 2015 0.3 1.3 30 0.5 1.5 30 20.6% -0.20 [$-0.91, 0.51$] 2015 Subtotal (95% Ch) 175 196 45.2% -0.21 [$-0.76, 0.33$] Heterogeneity: Tau" = 0.00; Chi" = 0.91, df = 3 ($P = 0.82$); P = 0% Test for overall effect: Z = 0.77 ($P = 0.44$) H1.2.4 6.13 months Petterogeneity: Tau" = 0.00; Chi" = 0.93, df = 2 ($P = 0.63$); P = 0% Test for overall effect: Z = 0.02 ($P = 0.98$); P = 0% Test for overall effect: Z = 0.02 ($P = 0.98$); P = 0% Test for overall effect: Z = 0.02 ($P = 0.98$); P = 0% Test for overall effect: Z = 0.02 ($P = 0.98$); P = 0% Test for overall effect: Z = 1.54 ($P = 0.22$); P = 21% Test for overall effect: Z = 1.54 ($P = 0.12$)											
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Stevens-Lapsley 2012				6.4	5.2		4.0%			
Subtotal (95% C) 75 72 10.8% -0.64 [-3.86, 2.59] Heterogeneity. Tau ² = 0.58; Ch ² = 10.47, df = 2 (P = 0.005); P = 81% Fest for overall effect $Z = 0.39$ (P = 0.70) H1.2.2 1-2 months Yaidés 2010 11.4 6.9 39 13.1 6.3 44 2.7% -1.70 [-4.56, 1.16] 2010 Stevens-Lapsley 2012 1.2 4 31 2.9 4.3 26 4.4% -1.70 [-3.87, 0.47] 2012 evine 2013 4.8 4.38 0.415 6.27 33 3.1% 0.66 [-2.00, 3.30] 2013 Demircioglu 2015 0.5 1.5 30 1.1 2.2 30 15.3% -0.60 [-1.55, 0.35] 2015 Subtotal (95% CI) 130 133 25.5% -0.72 [-1.52, 0.08] H1.2.3 3-4 months Peterson 2009 2 4.02 76 1.8 4.5 92 10.3% 0.20 [-1.09, 1.49] 2009 Aidés 2010 7.3 3.7 39 7.7 3.7 44 7.5% -0.40 [-1.99, 1.19] 2010 Stevens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% -0.80 [-2.49, 0.89] 2012 Demircioglu 2015 0.3 1.3 30 0.5 1.5 30 2.0.8% -0.20 [-0.91, 0.51] 2015 Subtotal (95% CI) 175 196 45.2% -0.21 [-0.76, 0.33] Heterogeneity. Tau ² = 0.00; ChP ² = 0.81; P ² 0% Fest for overall effect $Z = 1.77$ (P = 0.81; P ² 0% Fest for overall effect $Z = 0.77$ (P = 0.43) H1.2.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 Sevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% 0.60 [-1.23, 2.43] 2012 evine 2013 2.58 2.86 26 3.54 6.05 24 3.1% -0.96 [-3.82, 1.70] 2013 Heterogeneity. Tau ² = 0.00; ChP ² = 0.93; df = 2 (P = 0.63); P ² 0% Fest for overall effect $Z = 1.77$ (CP = 0.43) H1.2.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 Sevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% 0.60 [-1.23, 2.43] 2012 evine 2013 2.58 2.86 26 3.54 6.05 24 3.1% -0.96 [-3.82, 1.70] 2013 Heterogeneity. Tau ² = 0.00; ChP ² = 0.93; df = 2 (P = 0.63); P ² = 0% Fest for overall effect $Z = 1.54$ (P = 0.12) For overall effect $Z = 1.54$ (P = 0.12) Fest for overall effect $Z = 1.54$ (P = 0.12) Fest for overall effect $Z = 1.54$ (P = 0.12)	íoshida b 2017	5	5		4	4					
Heterogeneity: Tau ² = 6.58; Chi ² = 10.47, df = 2 (P = 0.005); I ² = 81% Test for overall effect Z = 0.39 (P = 0.70) 11.2.2 1-2 months Yaldés 2010 11.4 6.9 39 13.1 6.3 44 2.7% -1.70 [-4.56, 1.16] 2010 Stevens-Lapsley 2012 1.2 4 31 2.9 4.3 26 4.4% -1.70 [-3.87, 0.47] 2012 Levine 2013 4.8 4.38 30 4.15 6.27 33 3.1% 0.65 [-2.00, 3.30] 2013 Demircioglu 2015 0.5 1.5 30 1.1 2.2 30 15.3% -0.00 [-1.55, 0.35] 2015 Subtotal (95% Cl) 130 133 25.5% -0.72 [-1.52, 0.08] Heterogeneity: Tau ² = 0.00; Chi ² = 2.32, df = 3 (P = 0.51); I ² = 0% Test for overall effect Z = 1.77 (P = 0.08) 11.2.3 3.4 months Petterogeneity: Tau ² = 0.00; Chi ² = 0.32; J ² = 0% Test for overall effect Z = 0.77 (P = 0.44) 11.2.4 6-13 months Petterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 3 (P = 0.82); I ² = 0% Test for overall effect Z = 0.07 (Chi ² = 0.93), df = 2 (P = 0.63); I ² = 0% Test for overall effect Z = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); I ² = 0% Test for overall effect Z = 0.07 (Chi ² = 0.93), df = 2 (P = 0.63); I ² = 0% Test for overall effect Z = 0.07 (Chi ² = 0.93), df = 2 (P = 0.63); I ² = 0% Test for overall effect Z = 0.07 (Chi ² = 0.93), df = 2 (P = 0.63); I ² = 0% Test for overall effect Z = 0.07 (Chi ² = 0.93), df = 2 (P = 0.63); I ² = 0% Test for overall effect Z = 0.07 (Chi ² = 0.93), df = 2 (P = 0.63); I ² = 0% Test for overall effect Z = 0.07 (Chi ² = 0.93), df = 2 (P = 0.63); I ² = 0% Test for overall effect Z = 1.54 (P = 0.12) Test for overall effect Z = 1.54 (P = 0.12)		5	4		4	4				2017	
Test for overall effect: $Z = 0.39$ (P = 0.70) 11.2. 21 - 2 months (aldés 2010 11.4 6.9 39 13.1 6.3 44 2.7% -1.70 [-4.56, 1.16] 2010 Stevens-Lapsley 2012 1.2 4 31 2.9 4.3 26 4.4% -1.70 [-3.87, 0.47] 2012 cevine 2013 4.8 4.38 30 4.15 6.27 33 3.1% 0.65 [-2.00, 3.30] 2013 Demicricipally 2015 0.5 1.5 30 1.1 2.2 30 15.3% -0.60 [-1.55, 0.35] 2015 Demicricipally 2015 0.5 1.5 30 1.1 2.2 30 15.3% -0.60 [-1.55, 0.35] 2015 Demicricipally 2015 0.5 1.5 30 1.1 2.2 30 15.3% -0.60 [-1.55, 0.35] 2015 Subtotal (95% CI) 130 133 25.5% -0.72 [-1.52, 0.08] Test for overall effect: $Z = 1.77$ (P = 0.08) 11.2.3 -4 months Petterson 2009 2 4.02 76 1.8 4.5 92 10.3% 0.20 [-1.09, 1.49] 2009 Addés 2010 7.3 3.7 39 7.7 3.7 44 7.5% -0.40 [-1.99, 1.19] 2010 Stevens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% -0.80 [-2.49, 0.89] 2012 Demicricipally 2015 0.3 1.3 30 0.5 1.5 30 20.6% -0.20 [-0.91, 0.51] 2015 Subtotal (95% CI) 175 196 45.2% -0.20 [-0.91, 0.51] 2015 Test for overall effect: $Z = 0.77$ (P = 0.44) 11.2.4 6.13 months Test for overall effect: $Z = 0.77$ (P = 0.44) 11.2.4 6.13 months Test for overall effect: $Z = 0.00$; Chi ² = 0.93, df = 2 (P = 0.63); I ² = 0% Test for overall effect: $Z = 0.00$; Chi ² = 0.93, df = 2 (P = 0.63); I ² = 0% Test for overall effect: $Z = 0.00$; Chi ² = 0.93, df = 2 (P = 0.63); I ² = 0% Test for overall effect: $Z = 0.02$ (P = 0.98) Total (95% CI) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity; Tau ² = 0.01; Chi ² = 1.54 (P = 0.12) Total (95% CI) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); I ² = 21% Test for overall effect $Z = 1.54$ (P = 0.12)	Subtotal (95% CI)			75			72	10.8%	-0.64 [-3.86, 2.59]		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Heterogeneity: Tau ² = 6.5	i8; Chi² =	10.47	7, df = 2	(P = 0.0	005); F	² = 81 %	, ,			
	Fest for overall effect: Z =	0.39 (P :	= 0.70)							
Revens-Lapsley 2012 1.2 4 31 2.9 4.3 26 4.4% $-1.70[3.87, 0.47]$ 2012 Lewine 2013 4.8 4.38 30 4.15 6.27 33 3.1% $0.65[2.00, 3.30]$ 2013 biubtotal (95% CI) 130 133 25.5% $-0.60[1.55, 0.35]$ 2015 biubtotal (95% CI) 130 133 25.5% $-0.60[1.52, 0.08]$ rest for overall effect: Z = 1.77 (P = 0.08) 1.2.3 3.4 months Petterson 2009 2 4.02 76 1.8 4.5 92 10.3% $0.20[1.09, 1.49]$ 2009 addé s 2010 7.3 3.7 39 7.7 3.7 44 7.5% $-0.40[1.99, 1.19]$ 2010 bitwens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% $-0.80[2.49, 0.89]$ 2012 permicioglu 2015 0.3 1.3 30 0.5 1.5 30 20.6% $-0.20[0.91, 0.51]$ 2015 biubtotal (95% CI) 175 196 45.2% $-0.21[0.76, 0.33]$ Heterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 3 (P = 0.82); l ² = 0% rest for overall effect: Z = 0.77 (P = 0.44) 1.2.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% $-0.10[1.147, 1.27]$ 2009 bitwens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% 0.60[1.23, 2.43] 2012 cevine 2013 2.58 2.86 26 3.54 6.05 24 3.1% $-0.36[3.687, 0.10]$ Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); l ² = 0% rest for overall effect: Z = 0.02 (P = 0.98) rest for overall effect: Z = 0.02 (P = 0.98) rest for overall effect: Z = 0.02 (P = 0.98) rest for overall effect: Z = 1.54 (P = 0.12)	1.2.2 1-2 months										
tevens-Lapsley 2012 1.2 4 31 2.9 4.3 26 4.4% $-1.70[3.87, 0.47]$ 2012 evine 2013 4.8 4.38 30 4.15 6.27 33 3.1% $0.65[2.00, 3.30]$ 2013 permitroigul 2015 0.5 1.5 30 1.1 2.2 30 15.3% $-0.60[1.55, 0.35]$ 2015 is ubtatal (95% CI) 130 133 25.5% $-0.72[-1.52, 0.08]$ teverse-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% $-0.40[1.99, 1.49]$ 2009 addé s2010 7.3 3.7 39 7.7 3.7 44 7.5% $-0.40[1.99, 1.49]$ 2009 addé s2010 7.3 3.7 39 7.7 3.7 44 7.5% $-0.40[1.99, 1.49]$ 2019 tevens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% $-0.80[2.49, 0.89]$ 2012 permitroigul 2015 0.3 1.3 30 0.5 1.5 30 20.6% $-0.20[0.91, 0.51]$ 2015 tevens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% $-0.80[2.49, 0.89]$ 2012 permitroigul 2015 0.3 1.3 30 0.5 1.5 30 20.6% $-0.20[0.91, 0.51]$ 2015 tevens-Lapsley 2012 0.8 2.8 30 1.4 3.4 25 6.0% $-0.00[1.23, 2.43]$ 2012 est for overall effect Z = 0.77 (P = 0.44) 1.2.4 6-13 months tetterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% $-0.10[1.47, 1.27]$ 2009 tevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% $-0.00[1.23, 2.43]$ 2012 etwine 2013 2.58 2.86 26 3.54 6.05 24 3.1% $-0.05[3.62, 1.70]$ 2013 ubtatal (95% CI) 124 130 18.5% $-0.01[-1.02, 1.00]$ teterogeneity: Tau ² = 0.00; Chi ² = 0.93; df = 2 (P = 0.63); l ² = 0% est for overall effect Z = 0.77 (Chi ² = 1.6.50, df = 13 (P = 0.22); l ² = 0% est for overall effect Z = 1.54 (P = 0.12) 504 531 100.0% $-0.38[-0.87, 0.10]$	aldés 2010	11.4	6.9	39	13.1	6.3	44	2.7%	-1.70 [-4.56, 1.16]	2010	
Levine 2013 4.8 4.38 30 4.15 6.27 33 3.1% 0.65 [-2.00, 3.30] 2013 Demircioglu 2015 0.5 1.5 30 1.1 2.2 30 15.3% -0.60 [-1.55, 0.35] 2015 Subtotal (95% CI) 130 133 25.5% -0.72 [-1.52, 0.08] H12.3 3.4 months Petterson 2009 2 4.02 76 1.8 4.5 92 10.3% 0.20 [-1.09, 1.49] 2009 Aldés 2010 7.3 3.7 39 7.7 3.7 44 7.5% -0.40 [-1.99, 1.19] 2010 Stevens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% -0.80 [-2.49, 0.89] 2012 Demircioglu 2015 0.3 1.3 30 0.5 1.5 30 20.6% -0.20 [-0.76, 0.33] Heterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 3 (P = 0.82); l ² = 0% Test for overall effect: $Z = 0.77$ (P = 0.44) H12.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 Subtotal (95% CI) 175 196 45.2% -0.21 [-0.76, 0.33] Heterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 3 (P = 0.82); l ² = 0% Test for overall effect: $Z = 0.77$ (P = 0.44) H12.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 Subtotal (95% CI) 124 130 18.5% -0.01 [-1.02, 1.00] Heterogeneity: Tau ² = 0.00; Chi ² = 0.93); df = 2 (P = 0.63); l ² = 0% Test for overall effect: $Z = 0.02$ (P = 0.83) Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); l ² = 1% Test for overall effect: $Z = 1.54$ (P = 0.12) Feast for overall effect: $Z = 1.54$ (P = 0.12) Factor prevenal effect: $Z = 1.54$ (P = 0.12)											
Demircioglu 2015 0.5 1.5 30 1.1 2.2 30 15.3% -0.60 $[1.55, 0.35]$ 2015 Subtotal (95% CI) 130 133 25.5% -0.72 $[-1.52, 0.08]$ Heterogeneity: Tau ² = 0.00; Chi ² = 2.32, df = 3 (P = 0.51); P = 0% Fest for overall effect Z = 1.77 (P = 0.08) 11.2.3 3.4 months Petterson 2009 2 4.02 76 1.8 4.5 92 10.3% 0.20 $[-1.09, 1.49]$ 2009 /aldés 2010 7.3 3.7 39 7.7 3.7 44 7.5% -0.40 $[-1.99, 1.49]$ 2010 Stevens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% -0.80 $[-2.49, 0.89]$ 2012 Demircioglu 2015 0.3 1.3 30 0.5 1.5 30 20.6% -0.20 $[-0.31, 0.51]$ 2015 Subtotal (95% CI) 175 196 45.2% -0.21 $[-0.76, 0.33]$ Heterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 3 (P = 0.82); P = 0% Fest for overall effect Z = 0.77 (P = 0.44) 11.2.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% -0.10 $[-1.47, 1.27]$ 2009 Stevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% 0.60 $[-1.23, 2.43]$ 2012 Levine 2013 2.58 2.68 28 3.54 6.05 24 3.1% -0.96 $[-3.62, 1.70]$ 2013 Subtotal (95% CI) 124 130 18.5% -0.01 $[-1.02, 1.00]$ Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); P = 0% Fest for overall effect Z = 0.02; Ch ² = 0.98) Fotal (95% CI) 504 531 100.0% -0.38 $[-0.87, 0.10]$ Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); P = 21% Fest for overall effect Z = 1.54 (P = 0.12)											
Subtotal (95% CI) 130 133 25.5% $-0.72 [1.52, 0.08]$ Heterogeneity: Tau ² = 0.00; Chi ² = 2.32, df = 3 (P = 0.51); P = 0% Test for overall effect: Z = 1.77 (P = 0.08) 11.2.3 3-4 months Petterson 2009 2 4.02 76 1.8 4.5 92 10.3% 0.20 [-1.09, 1.49] 2009 valdés 2010 7.3 3.7 39 7.7 3.7 44 7.5% $-0.40 [-1.99, 1.19]$ 2010 Stevens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% $-0.80 [-2.49, 0.89]$ 2012 Demircioglu 2015 0.3 1.3 30 0.5 1.5 30 20.6% $-0.20 [-0.91, 0.51]$ 2015 Subtotal (95% CI) 175 196 45.2% $-0.21 [-0.76, 0.33]$ Heterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 3 (P = 0.82); I ² = 0% Test for overall effect: Z = 0.77 (P = 0.44) 11.2.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% $-0.10 [-1.47, 1.27]$ 2009 Stevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% 0.60 [-1.23, 2.43] 2012 Lewine 2013 2.58 2.86 26 3.54 6.05 24 3.1% $-0.96 [-3.62, 1.70]$ 2013 Subtotal (95% CI) 124 130 18.5% $-0.01 [-1.02, 1.00]$ Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); I ² = 0% Test for overall effect: Z = 0.02 (P = 0.98) Total (95% CI) 504 531 100.0% $-0.38 [-0.87, 0.10]$ Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); I ² = 21% -4 -2 0 2 4	Demircioalu 2015										
Heterogeneity: Tau ² = 0.00; Chi ² = 2.32, df = 3 (P = 0.51); I ² = 0% Test for overall effect: Z = 1.77 (P = 0.08) 11.2.3 3.4 months Petterson 2009 2 4.02 76 1.8 4.5 92 10.3% 0.20 [-1.09, 1.49] 2009 /aldés 2010 7.3 3.7 39 7.7 3.7 44 7.5% -0.40 [-1.99, 1.19] 2010 Stevens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% -0.20 [-0.91, 0.51] 2015 Demircioglu 2015 0.3 1.3 30 0.5 1.5 30 20.6% -0.20 [-0.91, 0.51] 2015 Subtotal (95% Cl) 175 196 45.2% -0.21 [-0.76, 0.33] Heterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 3 (P = 0.82); I ² = 0% Test for overall effect: Z = 0.77 (P = 0.44) 11.2.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 Stevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% 0.60 [-1.23, 2.43] 2012 .evine 2013 2.58 2.88 26 3.54 6.05 24 3.1% -0.96 [-3.62, 1.70] 2013 Subtotal (95% Cl) 124 130 18.5% -0.01 [-1.02, 1.00] Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); I ² = 0% Test for overall effect: Z = 0.02 (P = 0.98) Fotal (95% Cl) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); I ² = 21% Test for overall effect: Z = 1.54 (P = 0.12)				130			133				•
11.2.3 3.4 months Petterson 2009 2 4.02 76 1.8 4.5 92 10.3% 0.20 [-1.09, 1.49] 2009 /aldés 2010 7.3 3.7 39 7.7 3.7 44 7.5% -0.40 [-1.99, 1.49] 2009 /aldés 2010 7.3 3.7 39 7.7 3.7 44 7.5% -0.40 [-1.99, 1.9] 2010 Demircioglu 2015 0.3 1.3 30 0.5 1.5 30 20.6% -0.20 [-0.91, 0.51] 2015 Subtotal (95% CI) 175 196 45.2% -0.21 [-0.76, 0.33] -0.21 -0.21 -0.76, 0.33] Heterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 3 (P = 0.82); I ² = 0% Fest for overall effect: Z = 0.77 (P = 0.44) -0.10 [-1.47, 1.27] 2009 11.2.4 6-13 months -2 2 3.5 3.0 1.4 3.4 2.5 6.0% 0.60 [-1.23, 2.43] 2012 Levine 2013 2.58 2.86 2.6 3.54 6.05 2.4 3.1% -0.06 [-3.62, 1.70] 2013 Heterogeneity: Tau ² = 0.02; Chi ² = 0.93; df = 2 (P = 0.63); I ² = 0% <td< td=""><td>Heterogeneity: Tau² = 0.0</td><td>10; Chi² =</td><td>2.32.</td><td>df = 3</td><td>(P = 0.51</td><td>1); ² =</td><td>0%</td><td></td><td></td><td></td><td></td></td<>	Heterogeneity: Tau ² = 0.0	10; Chi ² =	2.32.	df = 3	(P = 0.51	1); ² =	0%				
Petterson 2009 2 4.02 76 1.8 4.5 92 10.3% 0.20 [-1.09, 1.49] 2009 /aldés 2010 7.3 3.7 39 7.7 3.7 44 7.5% -0.40 [-1.99, 1.19] 2010 Stevens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% -0.80 [-2.49, 0.89] 2012 Demircioglu 2015 0.3 1.3 30 0.5 1.5 30 20.6% -0.20 [-0.91, 0.51] 2015 Subtotal (95% Cl) 175 196 45.2% -0.21 [-0.76, 0.33] Heterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 3 (P = 0.82); I ² = 0% Test for overall effect: $Z = 0.77$ (P = 0.44) 11.2.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 Stevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% 0.60 [-1.23, 2.43] 2012 Levine 2013 2.58 2.86 26 3.54 6.05 24 3.1% -0.96 [-3.62, 1.70] 2013 Subtotal (95% Cl) 124 130 18.5% -0.01 [-1.02, 1.00] Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); I ² = 0% Test for overall effect: $Z = 0.02$ (P = 0.98) Total (95% Cl) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); I ² = 21% Test for overall effect: $Z = 1.54$ (P = 0.12)											
Petterson 2009 2 4.02 76 1.8 4.5 92 10.3% 0.20 [-1.09, 1.49] 2009 /aldés 2010 7.3 3.7 39 7.7 3.7 44 7.5% -0.40 [-1.99, 1.19] 2010 Stevens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% -0.80 [-2.49, 0.89] 2012 Demircioglu 2015 0.3 1.3 30 0.5 1.5 30 20.6% -0.20 [-0.91, 0.51] 2015 Subtotal (95% Cl) 175 196 45.2% -0.21 [-0.76, 0.33] Heterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 3 (P = 0.82); I ² = 0% Test for overall effect: $Z = 0.77$ (P = 0.44) 11.2.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 Stevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% 0.60 [-1.23, 2.43] 2012 Levine 2013 2.58 2.86 26 3.54 6.05 24 3.1% -0.96 [-3.62, 1.70] 2013 Subtotal (95% Cl) 124 130 18.5% -0.01 [-1.02, 1.00] Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); I ² = 0% Test for overall effect: $Z = 0.02$ (P = 0.98) Total (95% Cl) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); I ² = 21% Test for overall effect: $Z = 1.54$ (P = 0.12)											
The formation of the f											
Stevens-Lapsley 2012 0.8 2.8 30 1.6 3.8 30 6.8% -0.80 [-2.49, 0.89] 2012 Demircioglu 2015 0.3 1.3 30 0.5 1.5 30 20.6% -0.20 [-0.91, 0.51] 2015 Subtotal (95% Cl) 175 196 45.2% -0.21 [-0.76, 0.33] Heterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 3 (P = 0.82); I ² = 0% Test for overall effect: $Z = 0.77$ (P = 0.44) 11.2.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 Stevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% 0.60 [-1.23, 2.43] 2012 Levine 2013 2.58 2.86 26 3.54 6.05 24 3.1% -0.96 [-3.62, 1.70] 2013 Subtotal (95% Cl) 124 130 18.5% -0.01 [-1.02, 1.00] Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); I ² = 0% Test for overall effect: $Z = 0.02$ (P = 0.98) Total (95% Cl) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); I ² = 21% Test for overall effect: $Z = 1.54$ (P = 0.12)											
Demircioglu 2015 0.3 1.3 30 0.5 1.5 30 20.6% $-0.20[-0.91, 0.51]$ 2015 Subtotal (95% Cl) 175 196 45.2% $-0.21[-0.76, 0.33]$ Heterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 3 (P = 0.82); I ² = 0% Fest for overall effect: Z = 0.77 (P = 0.44) 11.2.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% $-0.10[-1.47, 1.27]$ 2009 Stevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% $0.60[-1.23, 2.43]$ 2012 Levine 2013 2.58 2.86 26 3.54 6.05 24 3.1% $-0.96[-3.62, 1.70]$ 2013 Subtotal (95% Cl) 124 130 18.5% $-0.01[-1.02, 1.00]$ Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); I ² = 0% Fest for overall effect: Z = 0.02 (P = 0.98) fortal (95% Cl) 504 531 100.0% $-0.38[-0.87, 0.10]$ Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); I ² = 21% Fest for overall effect: Z = 1.54 (P = 0.12)											
Subtotal (95% CI) 175 196 45.2% -0.21 [-0.76, 0.33] Heterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 3 (P = 0.82); ² = 0% Test for overall effect: $Z = 0.77$ (P = 0.44) 11.2.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 Stevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% 0.60 [-1.23, 2.43] 2012 Levine 2013 2.58 2.86 26 3.54 6.05 24 3.1% -0.96 [-3.62, 1.70] 2013 Subtotal (95% CI) 124 130 18.5% -0.01 [-1.02, 1.00] Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); ² = 0% Total (95% CI) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); ² = 21% Total (95% CI) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 1.54 (P = 0.12)											
Heterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 3 (P = 0.82); l ² = 0% Test for overall effect: $Z = 0.77$ (P = 0.44) 11.2.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 Stevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% 0.60 [-1.23, 2.43] 2012 Levine 2013 2.58 2.86 26 3.54 6.05 24 3.1% -0.96 [-3.62, 1.70] 2013 Subtotal (95% Cl) 124 130 18.5% -0.01 [-1.02, 1.00] Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); l ² = 0% Test for overall effect: $Z = 0.02$ (P = 0.98) Total (95% Cl) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); l ² = 21% Test for overall effect: $Z = 1.54$ (P = 0.12)		0.3	1.3		0.5	1.5				2015	
The stription over all effect: $Z = 0.77$ (P = 0.44) 11.2.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 Stevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% 0.60 [-1.23, 2.43] 2012 Levine 2013 2.58 2.86 26 3.54 6.05 24 3.1% -0.96 [-3.62, 1.70] 2013 Subtotal (95% Cl) 124 130 18.5% -0.01 [-1.02, 1.00] Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); l ² = 0% Fest for overall effect: $Z = 0.02$ (P = 0.98) Total (95% Cl) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); l ² = 21% Fest for overall effect: $Z = 1.54$ (P = 0.12)								45.2%	-0.21 [-0.76, 0.33]		
11.2.4 6-13 months Petterson 2009 0.3 4.02 68 0.4 4.5 81 9.4% -0.10 [-1.47, 1.27] 2009 Stevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% 0.60 [-1.23, 2.43] 2012 Levine 2013 2.58 2.68 2.6 3.54 6.05 24 3.1% -0.96 [-3.62, 1.70] 2013 Subtotal (95% Cl) 124 130 18.5% -0.01 [-1.02, 1.00] -0.01 [-1.02, 1.00] Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); i ² = 0% -0.38 [-0.87, 0.10] -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); i ² = 21% -0.38 [-0.87, 0.10] -4 -2 0 2 4 Test for overall effect: Z = 1.54 (P = 0.12) Favours levnerimentall Favours levnerimentall Favours levnerimentall Favours levnerimentall Favours levnerimentall					(P = 0.82)	2); l² =	0%				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Fest for overall effect: Z =	0.77 (P :	= 0.44)							
Stevens-Lapsley 2012 2 3.5 30 1.4 3.4 25 6.0% 0.60 [-1.23, 2.43] 2012 Levine 2013 2.58 2.86 26 3.54 6.05 24 3.1% -0.96 [-3.62, 1.70] 2013 Subtotal (95% CI) 124 130 18.5% -0.01 [-1.02, 1.00] Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); I ² = 0% Fest for overall effect: Z = 0.02 (P = 0.98) Fotal (95% CI) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); I ² = 21% Fest for overall effect: Z = 1.54 (P = 0.12) Levine 2013 2.58 2.86 26 3.54 6.05 24 3.1% Fest for overall effect: Z = 1.54 (P = 0.12)	1.2.4 6-13 months										
Levine 2013 2.58 2.86 26 3.54 6.05 24 3.1% -0.96 [-3.62, 1.70] 2013 Subtotal (95% Cl) 124 130 18.5% -0.01 [-1.02, 1.00] Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); ² = 0% Total (95% Cl) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); ² = 21% Test for overall effect: Z = 1.54 (P = 0.12) Test for overall effect: Z = 1.54 (P = 0.12)		0.3		68	0.4						
Subtotal (95% Cl) 124 130 18.5% -0.01 [-1.02, 1.00] Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); l ² = 0% Fest for overall effect: $Z = 0.02$ (P = 0.98) Fotal (95% Cl) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); l ² = 21% Fest for overall effect: $Z = 1.54$ (P = 0.12) Fest for overall effect: $Z = 1.54$ (P = 0.12)	Stevens-Lapsley 2012							6.0%			<u>_</u>
Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 2 (P = 0.63); i ² = 0% Test for overall effect: Z = 0.02 (P = 0.98) Fotal (95% Cl) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); i ² = 21% Test for overall effect: Z = 1.54 (P = 0.12) Feature (control)		2.58	2.86		3.54	6.05				2013	
Fest for overall effect: $Z = 0.02$ (P = 0.98) Fotal (95% CI) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); l ² = 21% -4 -2 0 2 Fest for overall effect: Z = 1.54 (P = 0.12) -4 -2 0 2 4								18.5%	-0.01 [-1.02, 1.00]		-
Fotal (95% CI) 504 531 100.0% -0.38 [-0.87, 0.10] Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); l ² = 21% Fest for overall effect: $Z = 1.54$ (P = 0.12) Fest for overall effect: $Z = 1.54$ (P = 0.12)					(P = 0.63	3); l² =	0%				
Heterogeneity: Tau ² = 0.17; Chi ² = 16.50, df = 13 (P = 0.22); l ² = 21% Test for overall effect: Z = 1.54 (P = 0.12) Festion overall effect: Z = 1.54 (P = 0.12)	Test for overall effect: Z =	0.02 (P	= 0.98)							
Test for overall effect: $Z = 1.54$ (P = 0.12) Feasible Constraints for overall effect: $Z = 1.54$ (P = 0.12)	fotal (95% CI)			504			531	100.0%	-0.38 [-0.87, 0.10]		•
Fest for overall effect: $Z = 1.54$ (P = 0.12) Fest for overall effect: $Z = 1.54$ (P = 0.12)	Heterogeneity: Tau ² = 0.1	7; Chi ² =	16.50), df = 1	3 (P = 0	.22); F	²= 21%	5			<u> </u>
Fest for subαroup differences: Chi ² = 1.51. df = 3 (P = 0.68). I ² = 0%											
					3 (P = (0.68).	² = 0%				Favours (experimental) Favours (control)

detected ($I^2 = 0\%$). The forest plot of SF-36 MCS was shown in **Figure 15**.

DISCUSSION

The purpose of this systematic review and meta-analysis was to explore the effect of NMES on quadriceps muscle strength, pain, and function following TKA. The most important finding of the current study was that postoperative NMES could improve the short-term to long-term quadriceps muscle strength, mid-term pain, and mid-term function following the TKA surgery.

Quadriceps muscle weakness is common following TKA (41). It was reported that 50–60% quadriceps muscle strength deficits might occur compared with the preoperative levels (23). Besides, quadriceps weakness has been found to increase joint loading and contribute to the progress of osteoarthritis (42, 43). It is a crucial goal to restore quadriceps strength for postoperative rehabilitation. Monaghan et al. systematically reviewed relative studies up to 2008. They did not find direct evidence to prove the advantage of NMES on quadriceps muscle strength recovery following TKA by limited (only two) included RCTs (44). Conley

et al. conducted a systematic review involving eight RCTs to assess the effect of NMES on quadriceps strength after knee surgery, such as anterior cruciate ligament reconstruction (n =5), TKA (n = 2), and meniscectomy (n = 1) (43). They revealed that NMES improved the recovery of quadriceps strength after the knee surgery with grade B evidence (43). Due to limited pieces of relevant literature published, some other reviews also failed to examine the effect of NMES on MVIC following TKA (45, 46). After including more RCTs that have been published recently, for the first time, we proved that NMES improved quadriceps muscle strength in terms of MVIC after TKA within 1 month, 1–2 months, 3–4 months, and 12–13 months with high-quality evidence.

After including only one published RCT, one previous review failed to explore the pooled effect of NMES on PCI following TKA (45). We found that NMES could not improve PCI after TKA with high-quality evidence.

There was a high risk of severe acute postoperative pain following TKA, undermining the recovery and delaying the fasttrack rehabilitation programs (47). Dabadghav et al. included 28 bilateral TKA patients following osteoarthritis. One knee received NMES plus exercise therapy randomly, and the other

	Expe	riment	tal	С	ontrol			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV. Random, 95% Cl
2.1.1 < 3 months										
Avramidis 2011	33.92	5.28	35	29.31	4.27	35	12.2%	4.61 [2.36, 6.86]	2011	
Stevens-Lapsley 2012	43	7.9	28	42.9	6.4	23	10.1%	0.10 [-3.82, 4.02]	2012	
Demircioglu 2015	59.6	16.5	30	44.4	21.5	30	4.5%	15.20 [5.50, 24.90]	2015	
Subtotal (95% CI)			93			88	26.8%	4.90 [-0.53, 10.34]		
leterogeneity: Tau ² = 10	5.38; Chi	² = 9.2	0, df =	2 (P = (0.01); I	² = 78%	6			
Test for overall effect: Z	= 1.77 (F	P = 0.0	8)							
2.1.2 3-6 months										
Petterson 2009	44.45	8.2	76	44.64	8.77	92	11.8%	-0.19 [-2.76, 2.38]	2009	-+-
Avramidis 2011	46.6	5.13		37.63		35	11.6%	8.97 [6.24, 11.70]		
Stevens-Lapsley 2012	49	7.6	25	45.8	8.5	21	9.2%	3.20 [-1.50, 7.90]		+
Demircioglu 2015	68.5	14.8	30	67.8	14.5	30	6.2%	0.70 [-6.71, 8.11]		
Subtotal (95% CI)			166			178	38.8%	3.39 [-1.91, 8.68]		
Heterogeneity: Tau ² = 24	4.06: Chi	² = 23.	81. df :	= 3 (P <	0.000	1): ² =	87%			
Test for overall effect: Z	•			- (.,				
2.1.3 > 6 months										
Petterson 2009	46.05	8.2	68	46.74	8.77	81	11.6%	-0.69 [-3.42, 2.04]	2009	
vramidis 2011	53.9	4.26	35	47.37	3.84	35	12.5%	6.53 [4.63, 8.43]	2011	
Stevens-Lapsley 2012	52.6	5.9	27	50.7	7.4	21	10.2%	1.90 [-1.97, 5.77]	2012	
Subtotal (95% CI)			130			137	34.4%	2.68 [-2.23, 7.58]		
leterogeneity: Tau ² = 1	6.60; Chi	² = 19.	25, df :	= 2 (P <	0.000	1); ² =	90%			
Test for overall effect: Z	= 1.07 (F	P = 0.2	8)							
rotal (95% CI)			389			403	100.0%	3.54 [1.04, 6.05]		◆
Heterogeneity: Tau ² = 1	2.09; Chi	² = 52.	27, df :	= 9 (P <	0.000	01); l² =	= 83%		-	
Test for overall effect: Z										-20 -10 0 10 20
Test for subaroup differe	•									Favours [control] Favours [experimental]

FIGURE 14 | Forest plots of meta-analysis of the effect of NMES vs. conventional rehabilitation on SF-36 PCS.

		Expe	erimen	tal	c	ontrol			Mean Difference		Mean Difference
Study or	Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
2.2.1 < 3	months										
Avramidis	s 2011	42.69	5.93	35	42.08	5.45	35	16.7%	0.61 [-2.06, 3.28]	2011	
Stevens-L	Lapsley 2012	56.8	9.4	28	53.7	7.5	23	9.9%	3.10 [-1.54, 7.74]	2012	
Demirciog		71.9	13	30	58.6	15.9	30	5.1%	13.30 [5.95, 20.65]	2015	
Subtotal	. ,			93			88	31.7%	4.79 [-1.25, 10.82]		
Heteroge	neity: Tau ² = 22	2.12; Ch	i ² = 10.	.26, df	= 2 (P =	0.006);	l² = 81	%			
Test for o	verall effect: Z	= 1.56 (P = 0.1	2)							
2.2.2 3-6	months										
Petterson	2009	57.17	7.66	76	56.77	88.27	92	1.0%	0.40 [-17.72, 18.52]	2009	
Avramidis	s 2011	53.51	4.2	35	49.2	4.23	35	19.8%	4.31 [2.34, 6.28]		
Stevens-I	Lapsley 2012	57.9	8.2	25	54.2	9.7	21	8.4%	3.70 [-1.55, 8.95]	2012	+
Demirciog	glu 2015	65.1	12.1	30	60.9	15.8	30	5.4%	4.20 [-2.92, 11.32]	2015	+
Subtotal	(95% CI)			166			178	34.6%	4.20 [2.41, 5.98]		•
Heteroge	nelty: Tau ² = 0.	.00; Chl ²	= 0.22	2, df = 3	6 (P = 0.	98); l² =	0%				
Test for o	verall effect: Z	= 4.62 (P < 0.0	00001)							
2.2.3 > 6	months										
Petterson	2009	56.63	7.66	68	57.16	88.27	81	0.9%	-0.53 [-19.84, 18.78]	2009	
Avramidis	s 2011	50.49	5.32	35	50.1	3.69	35	19.0%	0.39 [-1.75, 2.53]	2011	
	Lapsley 2012	57.8	4.4	27	54.8	6.9	21	13.8%	3.00 [-0.39, 6.39]	2012	
Subtotal				130			137	33.7%	1.12 [-0.68, 2.93]		▼
-	neity: Tau ² = 0. verall effect: Z			-	? (P = 0.	44); l² =	0%				
Total (95				389			403	100.0%	2.97 [1.11, 4.82]		
	neity: Tau ² = 3.				9 (P = 0).04); l²	= 50%				-20 -10 0 10 20
	verall effect: Z										Favours [control] Favours [experimental]
Test for s	ubaroup differe	ences: C	hi² = 6.	.09. df	= 2 (P =	0.05). I	² = 67.2	2%			. arears [astron] - arears [axpennental]
FIGURE 15	Forest plots of	of meta-	analys	is of th	e effect	t of NM	ES vs.	conventio	onal rehabilitation on S	SF-36 MC	S.
			.,				_				

knee received exercise merely. After immediate postsurgical rehabilitation of 7 days, no significant difference between the two knees in terms of pain was detected (48). A matched comparison

trial demonstrated that patients using the home-based NMES in the first 6 weeks relieved the pain (49). There was no previous meta-analysis that has evaluated the effect of NMES

on postoperative pain after TKA. We included five RCTs and found that NMES improved postoperative pain at mid-term (1–2 months and 3–6 months) following TKA. However, the improved differences did not reach the minimal clinically important difference (MCID) in pain (50).

WOMAC is one of the most commonly used questionnaires that assess symptoms and physical function in patients with lower limb osteoarthritis (51, 52). Additional NMES therapy of 8 weeks to exercise could not improve the WOMAC in patients with knee OA (53). No previous meta-analysis pooled analyzed the effect of NMES on postoperative function after TKA. We found that NMES improved postoperative WOMAC slightly at mid-term (3–4 months) following TKA with high-quality evidence.

After a matched comparison trial of 6 weeks, patients who used the home-based NMES improved TUG compared with patients in the control group following TKA (49). No previous meta-analysis analyzed the effect of NMES on postoperative TUG following TKA. With high-quality evidence, we found that NMES improved the postoperative TUG at short-term (within 1 month) following TKA. Bruce-Brand et al. found that patients who received home-based NMES for 6 weeks improved the SCT results than patients who received standard care in knee osteoarthritis (54). We discovered that NMES could not improve postoperative SCT with low-quality evidence. The effect of NMES on early TUG (within 1 month) has not been explored in previous literature. The SCT comprises different movements, such as stair ascending, descending, and their transition (55), which may be hard for patients to conduct in the short-term following TKA.

We found that NMES improved postoperative 3MWT at midterm with high-quality evidence but not long-term with lowquality evidence. Another two RCTs reported the effect of NMES on 6MWT in our study. We found no significant difference between NMES and control groups in terms of 6MWT at midterm or long-term. The previous studies emphasized an excellent correlation between 3MWT and 6MWT. 3MWT was easier to learn and repeat than 6MWT for patients (30). The advantage of NMES was found in terms of 3MWT but not 6MWT. The discrepancy may be related to the limited RCTs.

We detected no advantage of NMES in ROM in the present study, such as knee flexion and extension. Dabadghav et al. included 28 postoperative bilateral TKA patients and randomly allocated one knee to NMES plus exercise, while the other knee received exercise (48). They demonstrated no additional effect in terms of ROM between the two knees from 28 bilateral TKA patients (48). Results from an RCT also showed that NMES could not improve the ROM of the hemiplegic shoulder in patients after stroke (56).

We included four RCTs (involving 344 participants) and found that NMES improved SF-36 MCS at mid-term (3–6 months). No differences were found in terms of MCS at shortterm or long-term. Besides, NMES could not improve PCS at short-term, mid-term, or long-term. A previous meta-analysis confirmed the advantage of NMES on SF-36 MCS at mid-term (12 weeks) by Bistolfi et al. (45). However, they did not explore the effect of NMES on SF-36 at other periods.

Compared with a previous meta-analysis, Bistolfi et al. only included four RCTs and pooled evaluate the effect of NMES

on SF-36 merely (45). The evidence to prove the advantage of NMES in TKA was limited. Given the insufficiency of available data for comparison, some other reviews failed to explore the quantized effect of NMES on TKA (43, 44, 46, 57, 58). As far as we knew, this was the first systematic review and meta-analysis to comprehensively explore the effect of NMES on quadriceps muscle strength, pain, and function following TKA. However, the differences did not reach the MCID in pain (50). Given the included studies adopt different scales in many essential outcomes, the SMD was used to calculate the total effect of quadriceps muscle strength and WOMAC, which may generate issues with heterogeneity.

The study has several limitations. First, all the included studies failed to achieve the performance bias, which contributed to the main bias of this systematic review and meta-analysis. Second, the programs of NMES were not standardized among the included RCTs, which contributes to the heterogeneity. Third, the sample size was relatively small.

CONCLUSION

As a supplementary treatment after TKA, postoperative NMES could improve the short-term to long-term quadriceps muscle strength, mid-term pain, and mid-term function following TKA. However, many outcomes failed to achieve statistically meaningful changes and MCID, thus the clinical benefits remained to be confirmed.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

BS and LP conceived and designed the analysis. LP and KW search studies from the databases and analyzed data. YZ, YW, and HS participated in the selection of the studies. LP, YW, and HS extract the data. KW, YZ, and BS participated in the quality assessment. LP drafted the manuscript. BS and YZ ensured the accuracy of the data and analysis. All authors have read and approved the manuscript.

FUNDING

This study was supported through grants from the National Natural Science Foundation of China (81974347) and the Clinical Research Incubation project of West China Hospital, Sichuan University (2018HXFH040).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed. 2021.779019/full#supplementary-material

REFERENCES

- Price AJ, Alvand A, Troelsen A, Katz JN, Hooper G, Gray A, et al. Knee replacement. *Lancet.* (2018) 392:1672– 82. doi: 10.1016/S0140-6736(18)32344-4
- Skou ST, Roos EM, Laursen MB, Rathleff MS, Arendt-Nielsen L, Simonsen O, et al. A randomized, controlled trial of total knee replacement. *N Engl J Med.* (2015) 373:1597–606. doi: 10.1056/NEJMoa1505467
- Mizner RL, Petterson SC, Stevens JE, Vandenborne K, Snyder-Mackler L. Early quadriceps strength loss after total knee arthroplasty. The contributions of muscle atrophy and failure of voluntary muscle activation. *J Bone Joint Surg Am.* (2005) 87:1047–53. doi: 10.2106/00004623-200505000-00016
- Li JW, Ma YS, Xiao LK. Postoperative pain management in total knee arthroplasty. Orthopaedic Surg. (2019) 11:755–61. doi: 10.1111/os.12535
- Bourne RB, Chesworth BM, Davis AM, Mahomed NN, Charron KD. Patient satisfaction after total knee arthroplasty: who is satisfied and who is not? *Clin Orthopaedics Related Res.* (2010) 468:57–63. doi: 10.1007/s11999-009-1119-9
- Yue C, Zhang X, Zhu Y, Jia Y, Wang H, Liu Y. Systematic review of three electrical stimulation techniques for rehabilitation after total knee arthroplasty. J Arthroplasty. (2018) 33:2330–7. doi: 10.1016/j.arth.2018.01.070
- Bohl DD, Li J, Calkins TE, Darrith B, Edmiston TA, Nam D, et al. Physical therapy on postoperative day zero following total knee arthroplasty: a randomized, controlled trial of 394 patients. *J Arthroplasty.* (2019) 34:S173– 7.e1. doi: 10.1016/j.arth.2019.02.010
- Hamilton DF, Beard DJ, Barker KL, Macfarlane GJ, Tuck CE, Stoddart A, et al. Targeting rehabilitation to improve outcomes after total knee arthroplasty in patients at risk of poor outcomes: randomised controlled trial. *BMJ*. (2020) 371:m3576. doi: 10.1136/bmj.m3576
- Gotlin RS, Hershkowitz S, Juris PM, Gonzalez EG, Scott WN, Insall JN. Electrical stimulation effect on extensor lag and length of hospital stay after total knee arthroplasty. *Arch Phys Med Rehabil.* (1994) 75:957– 9. doi: 10.1016/0003-9993(94)90671-8
- Hainaut K, Duchateau J. Neuromuscular electrical stimulation and voluntary exercise. Sports Med. (1992) 14:100– 13. doi: 10.2165/00007256-199214020-00003
- Enoka RM, Amiridis IG, Duchateau J. Electrical stimulation of muscle: electrophysiology and rehabilitation. *Physiology*. (2020) 35:40–56. doi: 10.1152/physiol.00015.2019
- Jones S, Man WD, Gao W, Higginson IJ, Wilcock A, Maddocks M. Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease. *Cochrane Database Syst Rev.* (2016) 10:Cd009419. doi: 10.1002/14651858.CD009419.pub3
- Alamer A, Melese H, Nigussie F. Effectiveness of neuromuscular electrical stimulation on post-stroke dysphagia: a systematic review of randomized controlled trials. *Clin Intervent Aging.* (2020) 15:1521–31. doi: 10.2147/CIA.S262596
- Carson RG, Buick AR. Neuromuscular electrical stimulationpromoted plasticity of the human brain. J Physiol. (2021) 599:2375–99. doi: 10.1113/JP278298
- Elbasan B, Akaya KU, Akyuz M, Oskay D. Effects of neuromuscular electrical stimulation and Kinesio Taping applications in children with cerebral palsy on postural control and sitting balance. *J Back Musculoskeletal Rehabil.* (2018) 31:49–55. doi: 10.3233/BMR-169656
- Hauger AV, Reiman MP, Bjordal JM, Sheets C, Ledbetter L, Goode AP. Neuromuscular electrical stimulation is effective in strengthening the quadriceps muscle after anterior cruciate ligament surgery. *Knee Surg Sports Traumatol Arthroscopy*. (2018) 26:399–410. doi: 10.1007/s00167-017-4669-5
- Miao Q, Qiang JH, Jin YL. Effectiveness of percutaneous neuromuscular electrical stimulation for neck pain relief in patients with cervical spondylosis. *Medicine*. (2018) 97:e11080. doi: 10.1097/MD.000000000011080
- Avramidis K, Strike PW, Taylor PN, Swain ID. Effectiveness of electric stimulation of the vastus medialis muscle in the rehabilitation of patients after total knee arthroplasty. *Arch Phys Med Rehabil.* (2003) 84:1850– 3. doi: 10.1016/S0003-9993(03)00429-5
- Petterson SC, Mizner RL, Stevens JE, Raisis L, Bodenstab A, Newcomb W, et al. Improved function from progressive strengthening interventions after total knee arthroplasty: a randomized clinical trial with an imbedded prospective cohort. *Arthritis Rheumatism.* (2009) 61:174–83. doi: 10.1002/art.24167

- Laufer Y, Snyder-Mackler L. Response of male and female subjects after total knee arthroplasty to repeated neuromuscular electrical stimulation of the quadriceps femoris muscle. *Am J Phys Med Rehabil.* (2010) 89:464– 72. doi: 10.1097/PHM.0b013e3181dd8c0e
- Avramidis K, Karachalios T, Popotonasios K, Sacorafas D, Papathanasiades AA, Malizos KN. Does electric stimulation of the vastus medialis muscle influence rehabilitation after total knee replacement? *Orthopedics*. (2011) 34:175. doi: 10.3928/01477447-20110124-06
- 22. Stevens-Lapsley JE, Balter JE, Wolfe P, Eckhoff DG, Kohrt WM. Early neuromuscular electrical stimulation to improve quadriceps muscle strength after total knee arthroplasty: a randomized controlled trial. *Phys Ther.* (2012) 92:210–26. doi: 10.2522/ptj.20110124
- Stevens-Lapsley JE, Balter JE, Wolfe P, Eckhoff DG, Schwartz RS, Schenkman M, et al. Relationship between intensity of quadriceps muscle neuromuscular electrical stimulation and strength recovery after total knee arthroplasty. *Phys Ther.* (2012) 92:1187–96. doi: 10.2522/ptj.20110479
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ. (editors). Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). *Cochrane*. (2021). Available online at: www.training. cochrane.org/handbook
- 25. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. (2009) 62:e1–34. doi: 10.1016/j.jclinepi.2009.06.006
- Meldrum D, Cahalane E, Conroy R, Fitzgerald D, Hardiman O. Maximum voluntary isometric contraction: reference values and clinical application. *Amyotrophic Lateral Sclerosis:*. (2007) 8:47–55. doi: 10.1080/17482960601012491
- Vllasolli TO, Orovcanec N, Zafirova B, Krasniqi B, Murtezani A, Krasniqi V, et al. Physiological cost index and comfort walking speed in two level lower limb amputees having no vascular disease. *Acta Informatica Medica*. (2015) 23:12–7. doi: 10.5455/aim.2015.23.12-17
- Mathias S, Nayak US, Isaacs B. Balance in elderly patients: the "get-up and go" test. Arch Phys Med Rehabil. (1986) 67:387–9.
- Bennell K, Dobson F, Hinman R. Measures of physical performance assessments: Self-Paced Walk Test (SPWT), Stair Climb Test (SCT), Six-Minute Walk Test (6MWT), Chair Stand Test (CST), Timed Up & Go (TUG), Sock Test, Lift and Carry Test (LCT), and Car Task. *Arthritis Care Res.* (2011) 63(Suppl. 11):S350–70. doi: 10.1002/acr.20538
- Iriberri M, Gáldiz JB, Gorostiza A, Ansola P, Jaca C. Comparison of the distances covered during 3 and 6 min walking test. *Respir Med.* (2002) 96:812– 6. doi: 10.1053/rmed.2002.1363
- Southard V, Gallagher R. The 6MWT: will different methods of instruction and measurement affect performance of healthy aging and older adults? J Geriatric Phys Ther. (2013). 36:68–73. doi: 10.1519/JPT.0b013e318264b5e8
- Laucis NC, Hays RD, Bhattacharyya T. Scoring the SF-36 in orthopaedics: a brief guide. J Bone Joint Surg Am. (2015) 97:1628–34. doi: 10.2106/JBJS.O.00030
- 33. Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. *Semin Arthritis Rheumatism.* (2014) 44:123–30. doi: 10.1016/j.semarthrit.2014.05.001
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. (2011) 343:d5928. doi: 10.1136/bmj.d5928
- 35. Takeshima N, Sozu T, Tajika A, Ogawa Y, Hayasaka Y, Furukawa TA. Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference? *BMC Med Res Methodol.* (2014) 14:30. doi: 10.1186/1471-2288-14-30
- 36. Valdés Vilches M, Fernández Ferreras T, Serra Tarragón N, Bujedo Pertejo A, San Segundo Mozo R, Molins Roca J. Feedback and neuromuscular electrical stimulation during an early phase of a rehabilitation programe after total knee arthroplasty. *Trauma*. (2010) 21:163–8.
- Levine M, McElroy K, Stakich V, Cicco J. Comparing conventional physical therapy rehabilitation with neuromuscular electrical stimulation after TKA. *Orthopedics*. (2013) 36:e319–24. doi: 10.3928/01477447-20130222-20
- 38. Demircioglu DT, Paker N, Erbil E, Bugdayci D, Emre TY. The effect of neuromuscular electrical stimulation on functional status and quality of life

after knee arthroplasty: a randomized controlled study. *J Phys Ther Sci.* (2015) 27:2501–6. doi: 10.1589/jpts.27.2501

- Yoshida Y, Ikuno K, Shomoto K. Comparison of the effect of sensorylevel and conventional motor-level neuromuscular electrical stimulations on quadriceps strength after total knee arthroplasty: a prospective randomized single-blind trial. Arch Phys Med Rehabil. (2017) 98:2364– 70. doi: 10.1016/j.apmr.2017.05.005
- 40. Klika AK, Yakubek G, Piuzzi N, Calabrese G, Barsoum WK, Higuera CA. Neuromuscular electrical stimulation use after total knee arthroplasty improves early return to function: a randomized trial. *J Knee Surg.* (2020). doi: 10.1055/s-0040-1713420. [Epub ahead of print].
- Meier W, Mizner RL, Marcus RL, Dibble LE, Peters C, Lastayo PC. Total knee arthroplasty: muscle impairments, functional limitations, and recommended rehabilitation approaches. *J Orthopaedic Sports Phys Ther.* (2008) 38:246– 56. doi: 10.2519/jospt.2008.2715
- Mikesky AE, Meyer A, Thompson KL. Relationship between quadriceps strength and rate of loading during gait in women. J Orthopaedic Res. (2000) 18:171–5. doi: 10.1002/jor.1100180202
- Conley CEW, Mattacola CG, Jochimsen KN, Dressler EV, Lattermann C, Howard JS. A comparison of neuromuscular electrical stimulation parameters for postoperative quadriceps strength in patients after knee surgery: a systematic review. *Sports Health.* (2021) 13:116–27. doi: 10.1177/1941738120964817
- Monaghan B, Caulfield B, O'Mathúna DP. Surface neuromuscular electrical stimulation for quadriceps strengthening pre and post total knee replacement. *Cochrane Database Syst Rev.* (2010) 2010:Cd007177. doi: 10.1002/14651858.CD007177.pub2
- Bistolfi A, Zanovello J, Ferracini R, Allisiardi F, Lioce E, Magistroni E, et al. Evaluation of the effectiveness of neuromuscular electrical stimulation after total knee arthroplasty: a meta-analysis. *Am J Phys Med Rehabil.* (2018) 97:123–30. doi: 10.1097/PHM.00000000000847
- Volpato HB, Szego P, Lenza M, Milan SL, Talerman C, Ferretti M. Femoral quadriceps neuromuscular electrical stimulation after total knee arthroplasty: a systematic review. *Einstein.* (2016) 14:77–98. doi: 10.1590/S1679-45082015RW3140
- Grosu I, Lavand'homme P, Thienpont E. Pain after knee arthroplasty: an unresolved issue. *Knee Surg Sports Traumatol Arthroscopy*. (2014) 22:1744– 58. doi: 10.1007/s00167-013-2750-2
- 48. Dabadghav R, Potdar A, Patil V, Sancheti P, Shyam A. Additional effect of neuromuscular electrical stimulation on knee extension lag, pain and knee range of motion in immediate postsurgical phase (0-2 weeks) in primary total knee arthroplasty patient. *Ann Transl Med.* (2019) 7(Suppl 7):S253. doi: 10.21037/atm.2019.09.79
- Delanois RE, Sodhi N, Acuna A, Doll K, Mont MA, Bhave A. Use of home neuromuscular electrical stimulation in the first 6 weeks improves function and reduces pain after primary total knee arthroplasty: a matched comparison. *Ann Transl Med.* (2019) 7:S254. doi: 10.21037/atm.2019.09.150
- Laigaard J, Pedersen C, Rønsbo TN, Mathiesen O, Karlsen APH. Minimal clinically important differences in randomised clinical trials on pain management after total hip and knee arthroplasty: a systematic review. Br J Anaesthesia. (2021) 126:1029–37. doi: 10.1016/j.bja.2021.01.021

- Walker LC, Clement ND, Deehan DJ. Predicting the outcome of total knee arthroplasty using the WOMAC score: a review of the literature. *J Knee Surg.* (2019) 32:736–41. doi: 10.1055/s-0038-1666866
- 52. Salaffi F, Leardini G, Canesi B, Mannoni A, Fioravanti A, Caporali R, et al. Reliability and validity of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in Italian patients with osteoarthritis of the knee. Osteoarthritis Cartilage. (2003) 11:551–60. doi: 10.1016/S1063-4584(03)00089-X
- 53. Mizusaki Imoto A, Peccin S, Gomes da Silva KN, de Paiva Teixeira LE, Abrahão MI, Fernandes Moça Trevisani V. Effects of neuromuscular electrical stimulation combined with exercises versus an exercise program on the pain and the function in patients with knee osteoarthritis: a randomized controlled trial. *BioMed Res Int.* (2013) 2013:272018. doi: 10.1155/2013/272018
- 54. Bruce-Brand RA, Walls RJ, Ong JC, Emerson BS, O'Byrne JM, Moyna NM. Effects of home-based resistance training and neuromuscular electrical stimulation in knee osteoarthritis: a randomized controlled trial. BMC Musculoskeletal Disord. (2012) 13:118. doi: 10.1186/1471-2474-13-118
- 55. Iijima H, Eguchi R, Shimoura K, Yamada K, Aoyama T, Takahashi M. Transcutaneous electrical nerve stimulation improves stair climbing capacity in people with knee osteoarthritis. *Sci Rep.* (2020) 10:7294. doi: 10.1038/s41598-020-64176-0
- 56. de Jong LD, Dijkstra PU, Gerritsen J, Geurts AC, Postema K. Combined arm stretch positioning and neuromuscular electrical stimulation during rehabilitation does not improve range of motion, shoulder pain or function in patients after stroke: a randomised trial. J Physiother. (2013) 59:245– 54. doi: 10.1016/S1836-9553(13)70201-7
- Chughtai M, Elmallah RD, Mistry JB, Bhave A, Cherian JJ, McGinn TL, et al. Nonpharmacologic pain management and muscle strengthening following total knee arthroplasty. *J Knee Surg.* (2016) 29:194–200. doi: 10.1055/s-0035-1569147
- Kittelson AJ, Stackhouse SK, Stevens-Lapsley JE. Neuromuscular electrical stimulation after total joint arthroplasty: a critical review of recent controlled studies. *Euro J Phys Rehabil Med.* (2013) 49:909–20.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Peng, Wang, Zeng, Wu, Si and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.